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A B S T R A C T
Background
Reducing high blood cholesterol, a risk factor for cardiovascular disease (CVD) events in people with and without a past history of
coronary heart disease (CHD) is an important goal of pharmacotherapy. Statins are the first-choice agents. Previous reviews of the
effects of statins have highlighted their benefits in people with coronary artery disease. The case for primary prevention, however, is
less clear.
Objectives
To assess the effects, both harms and benefits, of statins in people with no history of CVD.
Search methods
To avoid duplication of effort, we checked reference lists of previous systematic reviews. We searched the Cochrane Central Register of
Controlled Trials (Issue 1, 2007), MEDLINE (2001 to March 2007) and EMBASE (2003 to March 2007). There were no language
restrictions.
Selection criteria
Randomised controlled trials of statins with minimum duration of one year and follow-up of six months, in adults with no restrictions
on their total low density lipoprotein (LDL) or high density lipoprotein (HDL) cholesterol levels, and where 10% or less had a history
of CVD, were included.
Data collection and analysis
Two authors independently selected studies for inclusion and extracted data. Outcomes included all cause mortality, fatal and non-
fatal CHD, CVD and stroke events, combined endpoints (fatal and non-fatal CHD, CVD and stroke events), change in blood total
cholesterol concentration, revascularisation, adverse events, quality of life and costs. Relative risk (RR) was calculated for dichotomous
data, and for continuous data pooled weighted mean differences (with 95% confidence intervals) were calculated.
1Statins for the primary prevention of cardiovascular disease (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Main results
Fourteen randomised control trials (16 trial arms; 34,272 participants) were included. Eleven trials recruited patients with specific
conditions (raised lipids, diabetes, hypertension, microalbuminuria). All-cause mortality was reduced by statins (RR 0.84, 95% CI
0.73 to 0.96) as was combined fatal and non-fatal CVD endpoints (RR 0.70, 95% CI 0.61 to 0.79). Benefits were also seen in the
reduction of revascularisation rates (RR 0.66, 95% CI 0.53 to 0.83). Total cholesterol and LDL cholesterol were reduced in all trials
but there was evidence of heterogeneity of effects. There was no clear evidence of any significant harm caused by statin prescription or
of effects on patient quality of life.
Authors’ conclusions
Reductions in all-cause mortality, major vascular events and revascularisations were found with no excess of cancers or muscle pain
among people without evidence of cardiovascular disease treated with statins. Other potential adverse events were not reported and
some trials included people with cardiovascular disease. Only limited evidence showed that primary prevention with statins may be
cost effective and improve patient quality of life. Caution should be taken in prescribing statins for primary prevention among people
at low cardiovascular risk.
P L A I N L A N G U A G E S U M M A R Y
Statins for the primary prevention of cardiovascular disease
Cardiovascular disease (CVD) is ranked as the number one cause of mortality and is a major cause of morbidity world wide. Reducing
high blood cholesterol which is a risk factor for CVD events is an important goal of medical treatment. Statins are the first-choice
agents. Since the early statin trials were reported, several reviews of the effects of statins have been published highlighting their benefits
particularly in people with a past history of CVD.However for people without a past history of CVD (primary prevention), the evidence
is less clear. The aim of this systematic review is to assess the effects, both in terms of benefits and harms of statins for the primary
prevention of CVD. We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE and EMBASE until
2007. We found 14 randomised control trials with 16 trial arms (34,272 patients) dating from 1994 to 2006. All were randomised
control trials comparing statins with usual care or placebo. Duration of treatment was minimum one year and with follow up of a
minimum of six months. All cause mortality. coronary heart disease and stroke events were reduced with the use of statins as was the
need for revascularisations. Statin treatment reduced blood cholesterol. Taking statins did not increase the risk of adverse effects such
as cancer. and few trials reported on costs or quality of life. This current systematic review highlights the shortcomings in the published
trials and we recommend that caution should be taken in prescribing statins for primary prevention among people at low cardiovascular
risk.
B A C K G R O U N D
Burden of cardiovascular disease
Cardiovascular disease (CVD) encompasses a wide range of dis-
ease including ischaemic heart disease, coronary heart disease (e.g.
heart attack), cerebrovascular disease (e.g. stroke), raised blood
pressure, hypertension, rheumatic heart disease and heart failure.
The major causes of CVD are unhealthy diets, tobacco use and
physical inactivity (WHO 2008).
CVD is ranked as the number one cause ofmortality and is amajor
cause of morbidity world wide accounting for 17 million deaths,
30% of total deaths. Of these, 7.6 million are due to heart attacks
and 5.7 million due to stroke (WHO 2008). Over 80% of CVD
deaths occur in low and middle income countries (WHO 2008).
In developing countries, it causes twice a many deaths as HIV,
malaria and tuberculosis combined (Gaziano 2007). It has been
estimated that between 1990 and 2020, the increase in ischaemic
heart disease alonewill increase by 29% inmen and48% inwomen
in developed countries and by 120% in women and 127% in men
in developing countries (Yusuf 2001). CVD imposes high social
costs, including impaired quality of life and reduced economic
activity, and accounts for a large share of health service resources
(Gaziano 2007).
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CVD is multi-factorial in its causation and lifestyle changes are
the basis of any treatment strategy, with patients often requir-
ing behavioural counselling. Those unable to achieve or main-
tain adequate risk reduction on lifestyle changes alone or those at
high risk patients require pharmacotherapy. Reducing high blood
cholesterol (hypercholesterolaemia), a risk factor for both fatal and
non-fatal CVD events in people with and without a past CVD,
is an important goal of pharmacotherapy (Prospective Studies
Collaboration 2007). Statins are the first-choice agents for Low
Density Lipoprotein Cholesterol (LDL-C) reduction. The level at
which blood cholesterol is treated is more dependent on the abso-
lute reduction in risk that can be expected, given the patient’s other
risk factors, and taking into account the resources available for pre-
vention (Ramsay 1996). Since the relation between blood choles-
terol and cardiovascular risk is a continuous one (Chen 1991)
(although J-shaped in some studies for total mortality), there is
no definite threshold above which patients must be treated a pri-
ori. If a threshold for ’high’ cholesterol is set at over 3.8 mmol/L,
(146.9 mg/dL) this would contribute 4.4 million deaths world-
wide and40.4millionDALYs (disability adjusted life years) (Ezzati
2002). Furthermore, the average level of blood cholesterol within
a population is an important determinant of the CVD risk of the
population. Differences in average levels of blood cholesterol be-
tween populations are largely determined by differences in diet,
and countries with high dietary saturated fat intake and a low ra-
tio of polyunsaturated to saturated fatty acids have higher than
average cholesterol levels (Davey Smith 1992).
Trial evidence
Since the early statin trials were reported, several reviews of the
effects of statins have been published highlighting the benefits of
their use (Bartlett 2003; Blauw 1997; Briel 2004; Cheung 2004;
Ebrahim 1999; Katerndahl 1999; LaRosa 1994; LaRosa 1999;
Law 2003; Pignone 2000; Silva 2006; Thavendiranathan2006;
Ward 2007; Wilt 2004). In particular, an individual patient data
review and meta-analysis of 90,056 participants in 14 large ran-
domised controlled trials (RCTs) including the large Heart Pro-
tection Study (HPSCG 2003), followed up for 5 years, concluded
that statins were beneficial in reducing the risk of CVD events in
people at risk, and showed consistency of treatment benefits across
a wide range of patient subgroups (Baigent 2005). The evidence
on the beneficial effects of statins has led expert committees to
promote their use on a global scale particularly in the developed
world. (Manuel 2006; NICE 2006). Statin prescribing and expen-
diture have risen rapidly as a result. For example, the European
average (weighted by population of each country) increased from
11.12 defined daily doses/1000 in 1997 to 41.80/1000 in 2002,
an average 31% increase a year (Walley 2004). The expenditure
on statin drugs in England was over £20 million in 1993, over
£113 million in 1997 (Ebrahim 1998) and has risen to more than
£500 million in 2006 (NICE 2006).
Adverse effects of lowering cholesterol with
statins
There has been some concern that low levels of blood cholesterol
increase the risk of mortality from causes other than coronary
heart disease, including cancer, respiratory disease, liver disease and
accidental/violent death. Several studies have now demonstrated
that this is mostly, or entirely, due to the fact that people with
low cholesterol levels include a disproportionate number whose
cholesterol has been reduced by illness - early cancer, respiratory
disease, gastrointestinal disease and alcoholism, among others (
Iribarren 1997; Jacobs 1997). Thus it appears to be the pre-existing
disease which causes both the low cholesterol and raised mortality
(Davey Smith 1992).
The potential adverse effects of statins among people at low risk of
CVD are poorly reported and unclear (Jackson 2001) but, among
those with pre-existing CVD, the evidence suggests that any pos-
sible hazards are far outweighed by the benefits of treatment. Two
reviews of 18 and 35 trials respectively found that there were sim-
ilar rates of serious adverse events with statins as compared to
placebo (Kashani 2006; Silva 2006) and a further review of 26
RCTs concluded that there was no effect on risk of cancer with
statins (Dale 2006). Other adverse events have been investigated
and may be causal, for example rhabdomyolysis - break down of
muscles - which can be serious if not detected and treated early
(Beers 2003).However, in a systematic review of statins with about
35,000 people and 158,000 person years of observation in both
treated andplacebo groups, rhabdomyolysiswas diagnosed in eight
treated and five placebo patients, none with serious illness or death
(Law 2003). One RCT of 621 adults found that statins did not
adversely affect self reported quality of life, mood, hostility psy-
chological well being or anger expression (Wardle 1996). Small
decrements in scores on tests of psychomotor speed and attention
were found by Muldoon et al in an RCT of 209 adults, but Mul-
doon concluded that more research is needed to fully evaluate this
(Muldoon 2000). In addition, a systematic review of five statin
trials (N = 30,817) found no evidence that statins increased risk of
death from non-illness mortality (accidents, violence or suicide)
(Muldoon 2001).
Limitations of the reviews of the effects of
statins
Amajor limitation of the evidence summaries to date is the empha-
sis of the use of statins in secondary prevention of CVD without
distinguishingbetweenfindings in primary prevention trials.More
recently, however, a number of systematic reviews have focused
their attention of the use of statins in primary prevention but they
differ in their interpretation of the evidence to date (Brugts 2009;
Ebrahim 1999;Mills 2008; NICE 2006; Thavendiranathan2006;
Vrecer, 2003; Ward 2007). This is largely due to the differing in-
clusion criteria of the reviews and differences in reporting of out-
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comes. Where the most recent systematic review (Baigent 2005,
Brugts 2009; Mills 2008) promote the use of statins in the pri-
mary prevention of CVD (the latter team of authors received in-
dustry sponsorship), the evidence remains less clear leading other
authors to conclude that the assumed benefits of statin therapy in
secondary prevention trials should not be extrapolated to primary
prevention populations and that current cholesterol treatment
guidelines based on this assumption need to be revised (Abramson
2007).
The aim of this systematic review is to assess the effects of statins
for primary prevention of CVD. We planned to look for adverse
events associated with statins and examine effects in populations
such as elderly people and women.
O B J E C T I V E S
To assess the effects, both harms and benefits, of statins in people
with no history of CVD events.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs) comparing treatment with
statins for at least 12 months with placebo or usual care. Length
of follow-up of outcomes had to be at least six months.
Types of participants
Men and women (aged 18 or more) with no restrictions on total,
low or high density lipoprotein cholesterol levels. We limited our
inclusion of study population to have less or equal to 10% of a
previous history of CVD.
Types of interventions
Statins (HMG CoA reductase inhibitors) versus placebo or usual
care.
Concommitant interventions
Drug treatments and other interventions were accepted provided
they are given to both arms of the intervention groups. Adjuvant
treatments with one additional drug where a patient developed
excessively high lipids during the trial were accepted.
Types of outcome measures
The following outcomes were collected:
• death from all causes;
• fatal and non-fatal CHD, CVD and stroke events;
• combined endpoint (fatal and non-fatal CHD, CHD and
stroke events);
• change in blood total cholesterol concentration;
• revascularisation;
• adverse events;
• quality of life;
• costs.
Search methods for identification of studies
Asprevious comprehensive reviews (Bartlett 2005; Ebrahim 1999;
Ward 2007) have been undertaken we built on this work. We
searched the Cochrane Central Register of Controlled Trials
(CENTRAL) onThe Cochrane Library (Issue1, 2007),MEDLINE
(2001 to March 2007) and EMBASE (2003 to March 2007). A
standard RCT filter was used for MEDLINE (Dickersin 1994)
and EMBASE (Lefebvre 1996). No language restrictions were ap-
plied to either searching or trial inclusion. See Appendix 1 for
search strategies. Reference lists of identified review articles and of
all included RCTs were searched to find other potentially eligible
studies.
Data collection and analysis
Trial selection
Two reviewers independently read the results from searches on
electronic databases to identify those articles relevant to this sys-
tematic review based on title or title and abstract. Full articles were
retrieved for further assessment. The articles were read indepen-
dently by two reviewers and a form was designed to describe the
characteristics of studies to be included or excluded as set out in
the recommendations in the Cochrane Handbook 5.0.2 (Higgins
2009).
Assessment of risk of bias
We used criteria described in the Cochrane Handbook of System-
atic Reviews 5.0.2 (Higgins 2009) to describe the quality of tri-
als we found. Two authors independently assessed methodological
quality of selected studies (FT, KW). Any differences of opinion
were resolved by discussion and consensus and finally by discus-
sion with a third author (SE). To assess any risk of bias we focused
on the following dimensions as recommended in the Cochrane
Handbook:
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1. Adequate sequence generation (such as computer generated
random numbers and random number tables, whilst inadequate
approaches included the use of alternation, case record numbers,
birth dates or days of the week).
2. Adequate measures to conceal allocation. Concealment was
deemed adequate where randomisation is centralised or pharmacy-
controlled, or where the following are used: serially numbered con-
tainers, on-site computer-based systems where assignment is un-
readable until after allocation, other methods with robust methods
to prevent foreknowledge of the allocation sequence to clinicians
and patients.
3. Blinding was deemed adequate if blinding was applied (whether
the participant, care provider or outcome assessors)
4. Completeness of outcome data was deemed adequate if inten-
tion to treat analysis was performed for each outcome and not
what patient numbers the analysis was confined to.
5. Free of selective reporting: was deemed adequate if all stated
outcomes were reported on and presented. We will highlight any
selective outcome reporting.
A risk of bias graph for each trial was made available to assess
quality.
Data extraction
A data extraction form was designed and included:
• study ID;
• quality;
• participant baseline characteristics;
• intervention dosage and duration.
To assess baseline risk of CVD the following median/mean values
were also extracted:
• age;
• gender ratio;
• proportion of current smokers;
• total cholesterol, HDL and LDL cholesterol.
Outcome measures extracted included:
Primary outcome measures
• death from all causes;
• fatal and non-fatal CHD events,
• fatal and non-fatal CVD events
• fatal and non-fatal stroke events;
• combined endpoint (fatal and non-fatal CHD, CHD and
stroke events);
Secondary outcome measures
• change in blood total cholesterol concentration;
• revascularisation;
• adverse events;
• quality of life.
• costs.
Datawas extracted by two reviewers independently (FT,KW).Any
differences of opinion were resolved by discussion and consensus
and finally by discussion with a third reviewer (SE).
Contacting trialists
For unpublished studies or where data was incomplete in pub-
lished papers, attempts were made to contact the authors to obtain
further details.
Data analysis
Relative risk (RR) and 95% confidence intervals (CI) were cal-
culated for dichotomous data. Quantitative analyses of outcomes
was based on ’intention to treat’ (ITT). For continuous data (such
as change in blood total cholesterol), pooled weighted mean dif-
ferences (with 95% CI) were calculated.
We did not add the number of fatal and non-fatal clinical events
together from any of the studies that we included in this review as it
was not possible to ascertainwhether an individual who had a non-
fatal clinical event followed by a fatal clinical event was counted
as a clinical event under both categories. As a result we have only
included the composite of fatal and non-fatal clinical events if this
was reported in the papers. For example, number of stroke events:
seven trials reported this as a composite outcome, one reported on
fatal and one on non-fatal stroke events. We did not add the fatal
and non-fatal strokes together to ascertain a composite number.
Heterogeneity
Because trials found may not have been carried out according to a
commonprotocol therewill usually be variations in patient groups,
clinical settings, concomitant care etc.We, therefore, assessed het-
erogeneity between trial results. Trial data was considered to be
heterogeneous where the I2 statistic was > 50%. For analysis we
used the conservative, fixed effects method unless where data was
heterogenous in which case we used the random effects model.
Where significant heterogeneity was present, we attempted to ex-
plain the differences based on the patient clinical characteristics
and interventions of the included studies.
Publication or other bias
A funnel plot was used to test for the presence of publication bias
based on the data for the primary outcome of all cause mortality.
Publication bias is usually detected by asymmetry of the funnel
plot (Sterne 2001).
Analyses for potential effect modifiers was initially considered but
abandoned due to lack of adequate reporting. These were to in-
cluded:
• gender;
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• extent of hyperlipidaemia;
• age under 65, 65 and over.
Sensitivity analysis
Sensitivity analysis was used to explore the influence of the fol-
lowing on effect size:
• repeating analysis taking account of study quality;
• repeating analysis excluding any very long/large studies to
see how they influence the results.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies; Characteristics of studies awaiting classification.
After removal of duplicates, 4227 references were identified. From
reading titles and abstracts 4128 were eliminated as being not rel-
evant to the review. Full papers were obtained for 99 references.
From these 99 papers, 72 papers reporting on 48 studies were
excluded (see Characteristics of excluded studies). A total of 27
papers reporting on 14 trials were included (see Characteristics of
included studies). Checking the references of the recent systematic
reviews found 1 further trial (JUPITER 2008) which was pub-
lished outside the dates of our search, details of which are listed
in the Table: Characteristics of studies awaiting classification. Of
the 14, trials, two tested two different interventions; for the pur-
pose for meta analysis, each trial was counted as two trials (in total
16 trial arms) (CELL A 1996; CELL B 1996; PHYLLIS A 2004;
PHYLLIS B 2004). The trials dated from 1994 to 2006 and were
conducted world-wide, mainly in industrially developed countries
(Japan, USA and Europe). Twelve trials recruited patients with
specific conditions: eight recruited participants with raised lipids,
three with diabetes, two with hypertension and one with microal-
buminuria
All tested the effectiveness of a statin compared with placebo; nine
tested pravastatin 10-40mg per day; one atorvastatin 10mg per
day; two fluvastatin 40-80mg per day; two lovastatin 20-40mg per
day and the remaining simvastatin 40mg per day. Five trials also
included advice, counselling or information on health behaviour
modification such as diet, smoking cessation, exercise.
In total, the 14 trials (with 16 trial arms) recruited 34,272 partic-
ipants and observed outcomes ranging from 1-5.3 years, amount-
ing to approximately 113,000 patient years. The size of the pop-
ulation recruited ranged from 47- 8,009. The mean age of the
participants was 57 years (range 28-80 years), 65.9% were male
and of the five trials which reported on ethnicity; 91.4 % were
Caucasian.
Two trials (AFCAPS/TexCAPS 1998 and CARDS 2004) were
stopped prematurely because significant reductions in primary
composite outcomes between the intervention and placebo had
been observed. These trials had recruited 27.1% of the total study
population and were stopped 1.4-2.0 years before the official end
date. We were unable to estimate the number of potential patients
years of observation lost due to incomplete provision of data.
Data on all cause mortality was provided in eight trials. Excluding
the two trials whose primary outcome was change in size of carotid
artery, eight of the remaining trials chose a composite outcome as
their primary outcome. Despite this, seven provided data on fatal
and six on non-fatal CHD events and two on fatal and one on
non-fatal CVD events. Whilst eight trials reported on combined
stroke events, one provided data on non-fatal and one on fatal
stroke events. Nine trials provided data on cholesterol and seven
on adverse events. One provided economic costings, one provided
data on patient perceived quality of life Five trials provided data
on compliance: of those on statins, compliance ranged from 67%-
92% whilst for those on placebo 53%-93%.
Excluding the 3 trials which solely recruited participants with di-
abetes; 1-20% accounted for diabetics the other trials. Excluding
the two trials which recruited participants with hypertension; the
remaining studies had recruited 15-67% with hypertension. The
proportion of participants smoking ranged from 10-44% in the
13 trials which provided this data. We were unable to ascertain
baseline lipid levels for three trials. Baseline total cholesterol lev-
els ranged from 5.00-6.97 mmol/l (median 6.05 mmol/l), HDL
cholesterol from 1.07-1.46 mm/l (median 1.24 mm/l) and LDL
cholesterol from 2.92-4.95 mm/l (median 3.95mm/l).
Risk of bias in included studies
Four of the 16 trial arms did not provide adequate information on
the methods used for randomisation, three of which had recruited
more than 2000 participants. Fourteen trials used blinding to re-
duce bias, 10 of which used double blinding methods. Ten used
intention to treat analysis and the drop out rates for those that did
apply was ranged from2-17% (only two trials provided such data).
We judged 13 of the trials to be free from selective bias. (Figure
1; Figure 2). The MRC/BHF only provided data on total CVD
events for patients with diabetes in the primary prevention group,
whilst HYRIM did not present baseline and four-year follow-up
data on cholesterol.
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Figure 1. Methodological quality summary: review authors’ judgements about each methodological quality
item for each included study.
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Figure 2. Methodological quality graph: review authors’ judgements about each methodological quality
item presented as percentages across all included studies.
The funnel plot for all cause mortality showed no sign of publi-
cation bias (Figure 3). Only one trial was funded from taxation
(Ministery of Health) whilst the authors of nine trials reported
having been sponsored either fully or partially by pharmaceutical
companies (five by Bristol Myers and Squibb; two by Pfizer).
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Figure 3. Funnel plot of comparison: 2 Mortality and Morbidity, outcome: 2.1 Total Mortality.
Effects of interventions
All cause mortality (Analysis 2.1):
Eight trials with 28,161 participants recruited reported on total
mortality. During observation, 794 (2.8%) died with a death rate
of 1.0 per 100 person years of observation in the control groups.
None of the individual trials showed strong evidence of a reduc-
tion in total mortality but when the data were pooled using a fixed
effects model, a relative risk reduction which favoured statin treat-
ment by 16% was observed: (RR 0.84, 95% CI 0.73 to 0.96). No
heterogeneity was observed.
Fatal and non-fatal CHD events (Analysis 2.2, Analysis 2.3 and
Analysis 2.4)
Nine trials with 10 arms and 27,969 participants reported on
combined fatal and non-fatal CHD events: Four trials showed
evidence of a reduction in this combined outcome which was
maintained in the pooled analysis using a fixed effectsmodel: 1,577
(5.63%) events; RR 0.72 (95% CI 0.65-0.79).
Observations on fatal or non-fatal CHD events are based on less
than 55% of the participants recruited. Of the two trials which
had been stopped prematurely, only AFCAPS/TexCAPS presented
data on fatal CHD events. No significant risks reduction were
observed in fatal CHD events; 85/8823 (0.9%); RR 0.78 (95%CI
0.59-1.04) nor non-fatal CHD events 94/4927 (1.9%) non-fatal
CHD events; RR 0.74 (95%CI 0.50-1.10). No heterogeneity was
observed. .
Fatal and non-fatal CVD events (Analysis 2.5, Analysis 2.6 and
Analysis 2.7)
Six trials with 12,286 participants reported on combined fatal
and non-fatal CVD events. Two of the larger trials with 11,343
participants were able to demonstrate a significant reduction in
this combined outcome and this was maintained in the pooled
analysis using fixed effects model: 845 (6.8%) events; RR 0.74
(95% CI 0.66-0.85). There was no significant heterogeneity.
Two trials reported on fatal and one on non-fatal CHD events.
Reductions in risk were observed in these endpoints; fatal CVD
events;131/7,459 (1.7%); RR 0.70 (95% CI 0.50-0.99); nonfatal
CVD events - 39/864 (4.5%); RR 0.85 (95% CI 0.46-1.58).
Fatal and non-fatal stroke events (Analysis 2.8, Analysis 2.9 and
Analysis 2.10)
Seven trials with 21,556 participants reported on combined fatal
and non-fatal stroke events. Only one trial was stopped prema-
turely was able to demonstrate a significant reduction in this com-
bined outcome with the use of statins. The significant reduction
was maintained in the pooled analysis using a fixed effects model:
450 (2.1%) events; RR 0.78 (95% CI 0.65-0.94) Only one trial
with 6,595 participants reported on fatal stroke events and an-
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other one with 255 participants on non-fatal stroke events. No
significant risk reduction was seen for these endpoints; fatal stroke
events - 10/6595 (0.2%); RR 1.50 (95% CI 0.42-5.30) and non-
fatal stroke events, 1/255 (0.4); RR 2.98 (95%CI 0.12-72.39).
Combined fatal and non-fatal CHD, CVD and stroke events (
Analysis 2.11)
Only three trials with 17,452 participants reported a composite of
fatal and non-fatal events for CHD, CVD and stroke. All three of
the trials showed a significant reduction in this composite outcome
with the treatment of statins which was maintained in the pooled
analysis and using a fixed model: 938 (5.4%) events; RR 0.70
(95% CI 0.61-0.79)
Revascularisation (Analysis 1.4)
Five trials with 18,173 participants reported on the need for revas-
cularisation procedures during follow-up: 313 (1.7%) underwent
either PTCAorCABG.Twoof the larger trialswere able to demon-
strate fewer revascularisation events in the intervention groups
compared with the control groups with the use of statins and this
was maintained in the pooled analysis using a fixed effects model
were the a significant RR 0.66 (95% CI 0.53-0.83) was observed.
Cholesterol (Analysis 3.1 and Analysis 3.2)
Nine trials with 11 arms provided data on total and 11with 13 trial
arms on LDL cholesterol. Observations are based on 15,357and
22,413 participants respectively. For both endpoints all trials were
able to demonstrate significant reductions; total cholesterol a net
difference -0.89 mmol/L (95% CI -1.20 to -0.57 mmol/L) and
LDL cholesterol a net difference of -0.92 (95% CI -1.10 to -
0.74 mmol/L). There was marked heterogeneity of effects in both
analysis (I2= 99%). It is likely that the heterogeneity is due to
differences in the statin and dosage used- for example the dose of
pravastatin ranged from10mg to 40mg in different trials. It is also
possible that cholesterol outcomes were subject to reporting biases
in some trials which might exaggerate the findings.
Adverse events figures (Analysis 1.1; Analysis 1.2; Analysis 1.3;
Analysis 1.4; Analysis 1.5; Analysis 1.6; Analysis 1.7; Analysis 1.8;
Analysis 1.9; Analysis 1.10; Analysis 1.11; Analysis 1.12; Analysis
1.13; Analysis 1.14; Analysis 1.15; Analysis 1.16; Analysis 1.17
and Analysis 1.18)
Seven trials (eight trial arms) provided data on the following ad-
verse events: myalgia (muscle pain), rhabdomyolysis, cancer, lym-
phoma and melanoma. We also looked for data on changes in
muscle and liver enzyme, aspartate and alanine aminotransferase.
In total 3,385/19,555 (17.3%)participants experienced an adverse
event. Pooling the events rates indicated no difference between
the intervention and control groups with the use of statin using
a fixed effects model: RR 0.99 (95% 0.94-1.05) (Analysis 1.1).
No difference was also observed with the number of participants
stopping statin treatment due to adverse events, however there was
significant heterogeneity observed and a random effect model had
to be applied (Analysis 1.2).
Cancer: 793/17,277 (4.5%) participants in six trials developed
cancer (Analysis 1.5). No statistical differences were observed be-
tween the overall rates for cancer in the intervention and con-
trol groups nor in the subgroup analysis for individual can-
cers: prostrate, colon, lung, bladder, breast, gastro-intestinal, gen-
itor-urinary tract, respiratory tract. No significant heterogeneity
was observed in any of these comparisons. It is important to
note that the subgroups analysis are confined to only two trials
(AFCAPS/TexCAPS 1998 and WOSCOPS 1997) which pro-
vided these data.
The event rates for other adverse effects including lymphoma,
melanoma, myalgia, or rhabdomyolysis was low and ranged from
0.03% (rhabdomyolysis) to 7.4% (myalgia). No differences be-
tween groups were observed. No significant heterogeneity was ob-
served in any of these comparisons of the five trials which reported
on these events.
None of the trials reported on changes in muscle enzymes, aspar-
tate nor alanine aminotransferase. Two large trials reported that
4.4% (31/7031) of participants experienced changes in liver en-
zymes but the differences between the intervention and control
groups were of no statistical significance. There was no significant
heterogeneity.
Costs
One trial reported on costs. WOSCOPS which recruited men
with hypercholesterolaemia found that the use of statin yielded
substantial health benefits at a cost which was not prohibitive: an
undiscounted gain of 2,460 years of life at a cost of £8,121 per life
year gained.
Patient quality of life
There were no reliable data on patient quality of life. Cell A+B
provided limited data suggesting that the intervention of lifestyle
advise plus pravastatin reduced stress and sleeping problems.
Subgroups analysis
We intended do undertake subgroups analysis for gender, age, and
extent of hyperlipidaemia. However, none reported these break-
downs. No statistical differences in outcomes were observed in age
and sex.
Sensitivity analysis
We were unable to locate any unpublished studies. We, therefore,
confined our sensitivity analysis to study quality and to study size.
Study quality; since most of the trials used double blinding tech-
niques and intention to treat analysis and were free from selection
bias, we focused our attention on methods of randomisation. We
were unable to determine the method of randomisation for four
trials: Japanese MEGA, AFCAPS/TexCAPS; Aspen and HYRIM.
Sensitivity analysis indicated no change in the overall results due
methodof randomisationused (Analysis 5.1; Analysis 5.2; Analysis
5.3; Analysis 5.4; Analysis 5.5; Analysis 5.6; Analysis 5.7).
Study size: we confined our analysis to comparing large (>1000
participants) with small (<1000 participants) trials. Similarly,
sensitivity analysis did not alter the overall results (Analysis 5.8;
Analysis 5.9; Analysis 5.10; Analysis 5.11; Analysis 5.12; Analysis
5.13; Analysis 5.14).
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D I S C U S S I O N
The trials included in this systematic review showed reductions
in all-cause mortality, composite endpoints and revascularisations.
These findings were associated with falls in blood cholesterol and
LDL cholesterol in all trials reporting these outcomes but no ex-
cess of combined adverse events, cancers or specific biochemical
markers were found. Trials tended not to report single end points
of CHD or stroke events reflecting the small numbers of events
and that they were powered for composite endpoints. There was
limited evidence to suggest that the use of statins for primary pre-
vention may be cost effective and improve patient perceived qual-
ity of life. Sensitivity analysis suggested that age of participants or
size of trial did not alter the overall results.
Unlike previous reviews, we attempted to examine the effects of
statins in patients without evidence of existing cardiovascular dis-
eases and we attempted to examine specific outcomes rather than
composite outcomes. Although the trials intended to recruit only
people without evidence of CVD some trials did enter some with
participants with CVD . Rather than exclude such trials we set an
arbitrary threshold of 10% to avoid any major influence of effects
of treatment on those with existing CVD. Whilst our results con-
cur with some of the published data, our findings differ from oth-
ers. Specifically we concur with the results on all cause mortality
and adverse events in previous systematic reviews (Brugts 2009;
Ebrahim 1999; Mills 2008; NICE 2006). However, most of the
previous systematic reviews included trials where more than 10%
had a previous history of CVD. In two recently published reviews
the baseline all-cause mortality event rates were 1.4 per 100 person
years at risk (Mills 2008) and 1.7 per 100 person years (Brugts
2009) comparedwith 1.0per 100person years in this review.These
findings suggest that these recent reviews have tended to select tri-
als including sicker people than those included in our reviewwhich
aimed to target only trials of primary prevention. Consequently, it
is not surprising that findings for specific outcomes - rather than
composite outcomes - differ between reviews. For example our
review and one previous review (Thavendiranathan2006) did not
find strong evidence of any reduction in CHD mortality whereas
in a review where up to 50% of participants had suffered prior
CVD, a 54% reduction in CHD mortality was reported (Mills
2008) - reflecting the strong evidence that statins are beneficial in
secondary prevention. A major individual patient data meta-anal-
ysis - the Cholesterol Treatment Trialists’ Collaboration - of 14
trials including over 90,000 participants reported sub-group find-
ings in people without prior evidence of myocardial infarction or
other coronary heart disease and found large reductions in major
vascular endpoints (treated rate 8.5% vs. control rate10.6%; RR
0.78, 99% CIs 0.72 to 0.84) and major coronary events ( treated
rate 4.5% vs. control rate 6.1%; RR 0.72, 99% CIs 0.66, 0.80)
that were near identical to findings in people with prior CVD
(Baigent 2005). These findings have been criticized on the grounds
that the CTT collaborators did not disaggregate the primary and
secondary prevention findings but report on a group with “no
MI or other CHD” at baseline which includes a substantial num-
ber of people with pre-existing stroke, peripheral vascular disease
and diabetes which would have inflated the finding for absolute
risk reduction (Abramson 2007). Recently, theCTT collaboration
have published new analyses focusing on the comparison between
high and low doses of statins, including some relevant data on
the effects of statins in primary prevention (CTT Collaboration
2011). They report strong evidence of a reduction in major vas-
cular events in people without previous cardiovascular disease on
statins (RR 0.75, 95% CI 0.69, 0.82 per 1mmol/reduction in
LDL cholesterol) and a 0.4% lower risk difference per year in those
taking statins. Our estimate of the relative risk of major vascular
events is of similar magnitude and precision. Strong evidence of
the absence of any adverse effects on cancer risk is also confirmed
by the CTT Collaboration report.
It is important to remain cautious in interpreting our results for
combined end-points. In the majority of trials, power calculations
were based on composite outcomes and not on single outcomes.
Despite efforts to minimize bias in terms of blinding and use of
intention to treat analysis, over one third of trials reported out-
comes selectively. Eight trials did not report on adverse events at
all. Moreover, the majority of trials focused their attention on dif-
ferent combinations of outcomes to ascertain a composite out-
come. It was not always possible to ascertain or decipher these
i.e. whether an individual who had a non-fatal clinical event fol-
lowed by a fatal clinical event was counted as a clinical event under
both categories. As a result, much useful data for this systematic
review was lost. For example, the Japanese MEGA trials (whose
study populations account of 24% of the total) provided data on
combined fatal and non-fatal CHD events but not on fatal CHD
events and non-fatal CHD events separately.
Furthermore, two of the larger trials were prematurely stopped be-
cause significant reductions in primary composite outcomes had
been observed. This was also the case with the recently published
JUPITER trial of rosuvastatin in people with raised C-reactive
protein (JUPITER 2008) where the benefits of the reductions seen
in a composite outcome of major cardiovascular events and spe-
cific endpoints at two years into the trial were considered suffi-
cient to stop the trial. Nearly half the participants in the JUPITER
trial suffered with metabolic syndrome and the baseline all-cause
mortality rate in the control group was 1.25 per 100 patient years,
25% higher than in our systematic review. Early stopping of tri-
als is of particular concern because in this and other situations
early stopping may lead to an over-estimation of treatment effects
particularly when the number of events is small. (Bassler 2007;
Hlatky 2008; Montori 2005)
Caution also needs to be taken regarding the fact that all but one of
the trials had some form of pharmaceutical industry sponsorship.
It is now established that published pharmaceutical industry-spon-
sored trials are more likely than non-industry-sponsored trials to
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report results and conclusions that favour drug over placebo due to
biased reporting and/or interpretation of trial results (Als-Nielsen
2003). In primary prevention where world-wide the numbers of
patients eligible for treatment are massive, there might be motiva-
tions to use composite outcomes and early stopping to get results
that clearly support intervention.
Overall the populations sampled within this review were white,
male and middle aged. Therefore, caution needs to be taken re-
garding generalisability to older people who may be at greater risk
of side effects and to women who are at lower risk of CVD events.
Potential hazards of statins have been highlighted is small studies
and some, such as increased risk of cancers, can be discounted by
the evidence from the trials. However, even the more recent trials
have not assessed potentially important side effects (e.g. possible
cognitive impairments suggested by a small trial: Muldoon 2000)
or have played down real increases in risk of diabetes with intensive
cholesterol lowering (JUPITER 2008).
Twomajor trials were excluded from this review because of our cri-
terion of only including trials with fewer than 10% of participants
having a prior CVD diagnosis. ALLHAT-LLT (ALLHAT-LLT
2002) randomised 14% participants with a history of CHD
(other CVD diagnoses were not reported) and ASCOT-LLA
(ASCOT-LLA 2003) randomised 18% participants with a history
of stroke or TIA, peripheral vascular disease or other cardiovascu-
lar diseases. As these trials were predominantly of primary pre-
vention, their findings are of some relevance to the question of
primary prevention despite not fulfilling our criteria. ALLHAT-
LLT did not find any strong evidence of a reduction in all-cause
mortality (RR 0.99; 95%CI: 0.89 to 1.11) or in CHD deaths (RR
0.99; 95% CI: 0.84 to 1.16) in those randomised to pravastatin
compared to usual care. ASCOT-LLA, which randomised partic-
ipants to atorvastatin or placebo, also found no strong evidence
of a reduction in all-cause mortality (RR 0.87; 95% CI: 0.71 to
1.06) or in CVD mortality (RR 0.90; 95% CI: 0.66 to 1.23) de-
spite achieving much greater cholesterol lowering effects than ob-
served in ALLHAT-LLA. Combining evidence from these two
trials with the estimates made in this review, the effects for all-
cause mortality attenuate to RR 0.91; 95% CI: 0.84 to 0.99 and
for CVD mortality to RR 0.92; 95% CI: 0.81 to 1.05.
In an update to a previous review claiming that statins gave no
overall benefit in primary prevention (Therapeutics Letter 2003),
the effects on all-cause mortality in trials of statins for primary pre-
vention were RR 0.93, 95% CI: 0.86 to 1.00 and this attenuated
to RR 0.99, 95% CI: 0.90 to 1.08 when four trials with serious
risks of bias were excluded in a sensitivity analysis (Therapeutics
Letter 2010). On the basis of these findings and a recent meta-
analysis that managed to obtain data solely on patients without
prior CVD diagnoses from four large trials (ALLHAT-LLT 2002;
ASCOT-LLA 2003; PROSPER 2002; WOSCOPS 1997) and re-
ported a total mortality of RR 0.93, 95% CI: 0.86 to 1.00) (Ray
2010), it was concluded that any apparent mortality or net health
benefit of statins for primary prevention is more likely from tri-
als where various biases may have arisen rather than a real effect
(Therapeutics Letter 2010).
On the basis of our systematic review and these recent meta-anal-
yses, it is clear that any decision to use statins for primary preven-
tion should be made cautiously and in the light of an assessment
of the patient’s overall cardiovascular risk profile. Widespread use
of statins in people at low risk of cardiovascular events - below a
1% annual all-cause mortality risk or an annual CVD event rate of
below 2% observed in the control groups in the trials considered
here - is not supported by the existing evidence. Furthermore, the
tendency of trial protocols to remove patients suffering with co-
morbidities limits their generalisability to typical patient popula-
tions in whom decisions to prescribe statins have to made.
Our review is not able to comment on cost-effectiveness as, sur-
prisingly, few of the trials have published cost-effectiveness data
to support their contentions that these drugs are worth using for
primary prevention. Cost effectiveness analysis are price sensitive
and need to be reviewed in the light of changes in cost and changes
in prescribing (Ward 2007). Due to the assumed benefits of statin
therapy in secondary prevention trials, and the recent systematic
reviews (Baigent 2005; Brugts 2009; Mills 2008) concluding that
statin prescribing may improve survival and be of benefit in the
prevention CVD in people without cardiovascular disease, the
need for cost effectiveness analyses may be viewed as unneces-
sary. However, commentary on the JUPITER trial makes it clear
that decisions to treat ever more people with statins depends on
a careful appraisal of the balance of benefits to safety and costs
(Hlatky 2008). As noted by commentators, JUPITER demon-
strated that treating 120 people for 1.9 years with rosuvastatin
(at a cost of about US$287,000) would prevent one cardiovas-
cular event (http://blogs.nature.com/mfenner/2008/11/23/what-
are-the-right-numbers-for-jupiter; accessed 10 October 2010).
National Institute for Health & Clinical Excellence UK (NICE)
has provided some estimates based on data to 2005 and conclude
that an annual risk of a CHD event ranging from 3% to 0.5%, the
ranges of cost per quality adjusted life year gained (QALY) gained
were £10,000 to £31,000 at age 45 years, £13,000 to £40,000 at
age 55 years using older generic statins (NICE 2006). Their guid-
ance is to use statins “... as part of the management strategy for the
primary prevention of CVD for adults who have a 20% or greater
10-year risk of developing CVD.” Evidence supporting the use of
statins as part of an overall strategy of identification of people at
high risk of CVD events and lowering blood pressure and blood
cholesterol has been produced for low and middle income coun-
tries (Lim 2007) and is now part of World Health Organisation
policy for CVD prevention (WHO 2008b).
A U T H O R S ’ C O N C L U S I O N S
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Implications for practice
This current systematic review highlights the shortcomings in the
published trials of statins for primary prevention. Selective report-
ing and inclusion of people with cardiovascular disease in many
of the trials included in previous reviews of their role in primary
prevention make the evidence impossible to disentangle without
individual patient data. In people at high risk of cardiovascular
events due to their risk factor profile (i.e. 20+% 10-year risk), it
is likely that the benefits of statins are greater than potential short
term harms although long-term effects (over decades) remain un-
known. Caution should be taken in prescribing statins for primary
prevention among people at low cardiovascular risk.
Implications for research
As newer statins are developed it is likely that further trials will be
conducted in lower risk populations to extend the evidence base
particularly among younger people with adverse risk factor profiles
which are associated with higher life time CVD risk (Berry 2009).
It is important that these trials examine potential adverse effects of
statins and report on them in an unbiased way. Use of composite
outcomes is reasonable given the small number of events arising
among low risk populations but disaggregation of events by cause
is helpful for better understanding of the effects of statins and for
future systematic reviews of trials. More attention should be given
to studying possible cognitive impairment associated with use of
statins. Individual patient data meta-analyses have provided an
initial appraisal of the evidence available to 2011. Further updates
focusing on effects of statins among people without pre-existing
disease, examining a wider range of potential adverse effects and
for a range of predicted CVD risk would help clarify the role of
statins in primary prevention.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
ACAPS 1994
Methods Randomised trial 4x4 factorial
Participants 919 participants based in the USA aged 40 - 79 (mean age of 62); 52% male
Interventions 20mg lovastatin + 1mg warfarin versus placebo followed up for 34 months
Outcomes Carotid atherosclerosis, cholesterol, fatal + non-fatal CHD events, stroke
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Blocked randomisation stratified by centre
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Low risk Carers and patients were blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk
Selective reporting (reporting bias) Low risk
Adult Japanese MEGA Study
Methods Randomised trial
Participants 8009 participants with hypercholesterolaemia based in Japan aged 40-70 (mean age 59)
; 32% male
Interventions 10-20mg pravastatin versus placebo; all participants got advice on diet; follow-up 5 years
Outcomes Primary: composite of major CVD events, sudden cardiac death, angina and revascular-
isation. Single outcomes included: all cause mortality, total CVD events, fatal and non-
fatal MI, stroke and TIA events, sudden cardiac death, angina and revascularisation,
cholesterol, adverse events
Notes
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Adult Japanese MEGA Study (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
High risk open label for patients since placebo-controlled trials in Japan
are regarded with suspicion
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not described
Selective reporting (reporting bias) Low risk other than adverse events in detail
AFCAPS/TexCAPS 1998
Methods Randomised trial
Participants 6606 participants in Texas, USA; mean age 58; 57.5% male; 89% Caucasian
Interventions 20-40 mg lovastatin compared with placebo; follow-up for 5.2 years; all participants
received advice on diet
Outcomes Primary: composite of fatal and nonfatal MI and fatal CHD events. Single outcomes
included: all cause mortality, fatal and non-fatal CVD + stroke events, heart failure and
adverse events
Notes Trial was stopped prematurely. To be terminated when 320 participants had experienced
primary outcome event. Stopped when 267 had done so
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Low risk double blind-participants and personnel
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AFCAPS/TexCAPS 1998 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Intention to treat analysis used
Selective reporting (reporting bias) Low risk other than results for cholesterol
ASPEN 2006
Methods Randomised trial
Participants 2,410 participants with type 2 diabetes based in 16 developed countries with mean age
60; 62.5% male; 84% Caucasian
Interventions 10mg atorvastatin versus placebo; follow-up of 2.4 years (for primary prevention partic-
ipants)
Outcomes Primary: composite of fatal MI, stroke, sudden cardiac death, heart failure, CVD death.
Single outcomes included: non-fatal or silent MI + stroke, revascularisation, resuscitated
cardiac arrest, TIA, unstable angina, peripheral arterial disease, Ischaemic heart failure
and adverse events
Notes Primary prevention participants recruited 2-3 years into the study
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Low risk double-blind: participants and outcome assessors
Incomplete outcome data (attrition bias)
All outcomes
Low risk Intention to treat analysis used
Selective reporting (reporting bias) Low risk other than not providing results on adverse events for primary
prevention group
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CAIUS 1996
Methods Randomised trial
Participants 305 participants with hypercholesterolaemia based in Italy with mean age 55; 53% male
Interventions 40mg pravastatin versus placebo; follow-up of three years
Outcomes Slope of carotid artery, fatal and nonfatal MI, angina, revascularisations, cholesterol and
adverse events
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Independent co-ordinating centre controlled allocation
Allocation concealment (selection bias) Low risk Independent co-ordinating centre controlled allocation
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk double-blind: participants and personnel
Incomplete outcome data (attrition bias)
All outcomes
Low risk Intention to treat analysis used
Selective reporting (reporting bias) Low risk
CARDS 2004
Methods Randomised control trial
Participants 2838 participants with diabetes based in UK and Ireland aged 40-75 years (mean 61.7)
; 68% male; 94.5% Caucasian
Interventions 10mg atorvastatin, all patients were given counselling on cessation of smoking; follow
up of 3.9-4 years
Outcomes Primary: composite of fatal and nonfatal MI, acute CHD death, resuscitated cardiac
arrest. Single outcomes included: all cause mortality, fatal and non-fatal or silent MI
+ stroke, revascularisation, resuscitated cardiac arrest, total CVD events, adverse events
and cholesterol
Notes Trial stopped prematurely due to large beneficial treatment effect
Risk of bias
Bias Authors’ judgement Support for judgement
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CARDS 2004 (Continued)
Random sequence generation (selection
bias)
Low risk computer generated randomisation code
Allocation concealment (selection bias) Low risk Staff and patients unaware of computer generated randomi-
sation code
Blinding (performance bias and detection
bias)
All outcomes
Low risk triple-blind: participants, personnel and outcome assessors
Incomplete outcome data (attrition bias)
All outcomes
Low risk Intention to treat analysis used
Selective reporting (reporting bias) Low risk
CELL A 1996
Methods Randomised trial; 2x3 factorial design
Participants 228 participants with hyperlipidaemia based in Sweden with a mean age of 49; 85%
male
Interventions 10-40mg pravastatin plus intensive dietary advice versus placebo; follow-up for 18
months
Outcomes Fatal MI, cholesterol, quality of life.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Not described
Allocation concealment (selection bias) Low risk Randomisation performed separately for each
centre with numbers allocated to intervention
and control groups
Blinding (performance bias and detection
bias)
All outcomes
Low risk double-blind: participants and personnel
Incomplete outcome data (attrition bias)
All outcomes
Low risk Intention to treat analysis used
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CELL A 1996 (Continued)
Selective reporting (reporting bias) High risk adverse events rates not provided for each
group
CELL B 1996
Methods Randomised trial; 2x3 factorial design
Participants 227 participants with hyperlipidaemia based in Sweden with a mean age of 49; 85%
male
Interventions 10-40mg pravastatin plus dietary advice versus placebo; follow-up for 18 months
Outcomes Fatal MI, cholesterol, quality of life.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Not described
Allocation concealment (selection bias) Low risk Randomisation performed separately for each
centre with numbers allocated to intervention
and control groups
Blinding (performance bias and detection
bias)
All outcomes
Low risk double-blind: participants and personnel
Incomplete outcome data (attrition bias)
All outcomes
Low risk Intention to treat analysis used
Selective reporting (reporting bias) Unclear risk CVD and adverse events rates not provided for
each group
Derosa 2003
Methods Randomised trial
Participants 47 participants with hypercholesterolaemia based in Italy with a mean age of 51; 46%
male
Interventions 80mg fluvastatin versus placebo; all participants were given advice on diet and exercise ;
follow-up for one year
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Derosa 2003 (Continued)
Outcomes Adverse events, cholesterol.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Envelopes containing randomisation codes prepared by statisti-
cian
Allocation concealment (selection bias) Low risk Allocation code could only be identified by statistician and per-
son responsible for statistical analysis
Blinding (performance bias and detection
bias)
All outcomes
Low risk single blind: participants
Incomplete outcome data (attrition bias)
All outcomes
Low risk Intention to treat analysis used
Selective reporting (reporting bias) Low risk
HYRIM 2004
Methods Randomised trial 2x2 factorial design
Participants 287 men with hypertension based in Norway aged 40-75 years (mean age 57)
Interventions 40mg fluvastatin; follow up four years
Outcomes Primary: composite of fatal and nonfatal MI, + stroke, angina, sudden CHD death,
TIA and heart failure. MACE: composite of cardiac death, fatal and nonfatal MI and
revascularisation. Single outcomes included: adverse events, cholesterol
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Not described
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HYRIM 2004 (Continued)
Blinding (performance bias and detection
bias)
All outcomes
Low risk double-blind: participants and personnel
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not described
Selective reporting (reporting bias) Low risk mostly but not for adverse events and choles-
terol level at baseline and at 4 year follow-up
not provided
KAPS 1995
Methods Randomised trial
Participants 447 men based in Finland aged 44-65 years (mean 57)
Interventions 40mg pravastatin versus placebo; follow-up of 3 years
Outcomes Carotid atherosclerotic progression, total mortality, fatal and non-fatal MI events, stroke,
adverse events, cholesterol, other cardiac death, revascularisations, non cardiac death and
heart failure
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Biostatistician prepared randomisation scheme-
Allocation concealment (selection bias) Low risk Tablets were masked by pharmaceutical company
Blinding (performance bias and detection
bias)
All outcomes
Low risk double-blind: participants and personnel
Incomplete outcome data (attrition bias)
All outcomes
High risk 17% patients dropped out and were excluded from the analysis
Selective reporting (reporting bias) Low risk
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MRC/BHF Heart Protection
Methods randomised trial (2x2 factorial design)
Participants 3982 patients with no prior CHDwith diabetes mellitus as a subset of 20,536 UK adults
aged 40-80 years
Interventions 40mg simvastatin compared with placebo, follow up 5.3 years for all participants
Outcomes Composite of coronary and vascular events, stroke, revascularisations
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Not described
Allocation concealment (selection bias) Low risk Central telephone system used
Blinding (performance bias and detection
bias)
All outcomes
Low risk double blind: participants and outcome asses-
sors
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not described
Selective reporting (reporting bias) High risk only CVD event results provided for this sub-
group
PHYLLIS A 2004
Methods Randomised trial 4x4 factorial
Participants 253 men and women aged 45-70 (mean age 58) with hypertension, hypercholestero-
laemia and asymptomatic carotid atherosclerosis based in Italy
Interventions 25 mg hydrochlorothiazide + 40 mg pravastatin followed up for 2.6 years
Outcomes Primary outcomes: carotid atherosclerosis. Secondary outcomes: non-fatal MI, CVD
death, stroke, cholesterol and cancer
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
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PHYLLIS A 2004 (Continued)
Random sequence generation (selection
bias)
Low risk Randomisation was computer generate in blocks of 4
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Low risk
Incomplete outcome data (attrition bias)
All outcomes
Low risk
Selective reporting (reporting bias) Low risk
PHYLLIS B 2004
Methods Randomised trial 4x4 factorial
Participants 255 men and women aged 45-70 (mean age 58) with hypertension, hypercholestero-
laemia and asymptomatic carotid atherosclerosis based in Italy
Interventions 20 mg fosinopril + 40 mg pravastatin followed up for 2.6 years
Outcomes Primary outcomes: carotid atherosclerosis. Secondary outcomes: non-fatal MI, CVD
death, stroke, cholesterol and cancer
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was computer generate in blocks of
four.
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Low risk
Incomplete outcome data (attrition bias)
All outcomes
Low risk
Selective reporting (reporting bias) Low risk
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PREVEND IT 2004
Methods Randomised trial 2x2 factorial design
Participants 864 participants with microalbuminuria based in Holland aged 28-75 years (mean age
51); 64.5% male; 96% Caucasian
Interventions 40mg pravastatin versus placebo; follow-up 3.8 years
Outcomes Primary outcome: composite of fatal and non-fatal CVD events. Single outcomes in-
cluded fatal CVD events, stroke, heart failure, nonfatal MI and cholesterol
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was computer generated.
Allocation concealment (selection bias) Low risk Subjects randomised were allocated to a treat-
ment number.
Blinding (performance bias and detection
bias)
All outcomes
Low risk double blind
Incomplete outcome data (attrition bias)
All outcomes
High risk Intention to treat analysis confined to CVD
events, 6% dropped out
Selective reporting (reporting bias) Low risk
WOSCOPS 1997
Methods Randomised trial
Participants 6595 men with hypercholesterolaemia based in Scotland aged 45-64 (mean age 55)
Interventions 40mg pravastatin versus placebo; follow-up 4.9 years
Outcomes Primary outcome: composite of non-fatalMI andCHDdeath. Single outcomes included
total mortality, fatal CVD events, cholesterol, revascularisations, non-fatal MI and CHD
death and adverse events
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
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WOSCOPS 1997 (Continued)
Random sequence generation (selection
bias)
Low risk Not described
Allocation concealment (selection bias) Low risk All trial personnel remained unaware of the subject’s treatment
assignment throughout the study
Blinding (performance bias and detection
bias)
All outcomes
Low risk double-blind: participants and personnel
Incomplete outcome data (attrition bias)
All outcomes
Low risk Intention to treat analysis used
Selective reporting (reporting bias) Low risk
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
ALLHAT-LLT 2002 15% patients had history of CVD
Anderson 1993 No Placebo - Statin + antioxidant versus Statin + antioxidant
ASCOT-LLA 2003 18% patients had history of CVD
Bak 1998 Treatment length was only 6 months
BCAPS 2001 11% had history of CVD
Boccuzzi 1991 Not an RCT - all participants were given Simvastatin
Branchi Control Group was not randomised
Cassader 1993 Treatment length was only 24 weeks
Chan 1996 Treatment length is only nine months
CLIP 2002 Not an RCT - All participants were given Pravastatin
CRISP 1994 Treatment length is only 48 weeks
CURVES 1998 No Placebo - Statin Versus Statin
Dangas 1999 Treatment length is only six months
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(Continued)
Davidson 1997 No Placebo - Statin Versus Statin
Duffy 2001 Treatment length is only six months
Egashira 1994 Not an RCT - All participants were given Pravastatin
Eriksson 1998 No control group - Pravastatin vs. Cholestyramine
EXCEL 1990 Treatment length was only 48 weeks
FAST 2002 Over 40% had CVD and over 14% had CHD
Ferrari 1993 Treatment length is only 26 weeks
Gentile 2000 Treatment length was only 24 weeks
Glasser 1996 Length of treatment is only 12 weeks
Hokuriku NK-104 Study Not an RCT - All participants were given intravasating
Hufnagel 2000 Treatment length is only four months
Italian Family Physician Not an RCT - open labelled
Jardine 2006 Outcomes provided were aggregated. Unable to ascertain actual numbers for cardiac death and my-
ocardial infarction
Jones 1991 Length of treatment is only eight weeks
KLIS 2000 Not randomised
Lemaitre 2002 Cohort study
McGrae McDremott 2003 Subjects were not randomised to statins or no statins
Mohler 2003 Patients recruited had peripheral arterial disease
Muldoon 1997 Treatment length is only six months
Nephrotic Syndrome Study Treatment length was only nine months
Ohta 2000 Treatment length is only six months
Oi 1997 No placebo or control group
Ormiston 2003 Not an RCT - all participants were given statins
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(Continued)
Pitt 1999 No Placebo - Statins versus Angioplasty
POSCH 1990 Statins were not used
Pravastatin Multi 1993 Treatment length was only 26 weeks
PROSPER 2002 More than 10% of the participants had CVD
Sprecher 1994 Treatment length is only 24 weeks
Stein 1997 Treatment length is only four weeks
Su 2000 Treatment length is only six months
Tanaka 2001 Treatment length is only 12 weeks
Thomas 1993 Treatment length is only 24 weeks
Thrombosis Prevention Statins were not used
Wallace 2003 Treatment length was only 8 weeks
Yu-An 1998 Treatment length was less than one year
Characteristics of studies awaiting assessment [ordered by study ID]
JUPITER 2008
Methods Randomised trial
Participants 17,802 participants >50 years without history of CVD
Interventions Rosuvastatin 20 mg daily
Outcomes All cause mortality, fatal and non fatal CVD events, revascularisation
Notes Stopped prematurely
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D A T A A N D A N A L Y S E S
Comparison 1. Adverse Events
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Number of study participants
that had Adverse Events
8 19555 Risk Ratio (M-H, Fixed, 95% CI) 0.99 [0.94, 1.05]
2 Number of Study Participants
that Stopped Treatment Due to
Adverse Events
5 17328 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.85, 1.10]
3 Number of Study Participants
that were admitted to Hospital
1 1905 Risk Ratio (M-H, Fixed, 95% CI) 1.03 [0.74, 1.45]
4 Number of Study Participants
underwent revascularisation
5 18173 Risk Ratio (M-H, Fixed, 95% CI) 0.66 [0.53, 0.83]
5 Number of Study Participants
who developed cancer
7 17277 Risk Ratio (M-H, Fixed, 95% CI) 0.98 [0.85, 1.12]
6 Number of Study Participants
who develop Myalgia or muscle
pain
4 16464 Risk Ratio (M-H, Fixed, 95% CI) 0.96 [0.81, 1.14]
7 Number of Study Participants
who develop Rhabdomyolysis
1 6605 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.03, 3.20]
8 Number of Study Participants
who had elevated Liver
Enzymes
2 7031 Risk Ratio (M-H, Fixed, 95% CI) 1.58 [0.77, 3.25]
9 Number of Study Participants
that developed Prostate Cancer
1 6605 Risk Ratio (M-H, Fixed, 95% CI) 1.01 [0.78, 1.31]
10 Number of Study Participants
who developed Melanoma
2 13200 Risk Ratio (M-H, Random, 95% CI) 0.75 [0.39, 1.48]
11 Number of Study Participants
who developed Colon Cancer
1 6605 Risk Ratio (M-H, Fixed, 95% CI) 1.25 [0.70, 2.24]
12 Number of Study Participants
who developed Lung Cancer
1 6605 Risk Ratio (M-H, Fixed, 95% CI) 1.29 [0.69, 2.43]
13 Number of Study Participants
who develop Lymphoma
1 6605 Risk Ratio (M-H, Fixed, 95% CI) 1.09 [0.48, 2.47]
14 Number of Study Participants
who develop Bladder Cancer
1 6605 Risk Ratio (M-H, Fixed, 95% CI) 1.09 [0.48, 2.47]
15 Number of Study Participants
who develop Breast Cancer
1 6605 Risk Ratio (M-H, Fixed, 95% CI) 1.44 [0.62, 3.37]
16 Number who developed
Gastro-intestinal Cancers
1 6595 Risk Ratio (M-H, Fixed, 95% CI) 1.23 [0.73, 2.05]
17 Number of Study Participants
who developed Genito-urinary
tract Cancers
1 6595 Risk Ratio (M-H, Fixed, 95% CI) 0.96 [0.57, 1.63]
18 Number who developed
Respiratory Tract Cancers
1 6595 Risk Ratio (M-H, Fixed, 95% CI) 1.18 [0.67, 2.08]
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Comparison 2. Mortality and Morbidity
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Total Mortality 8 28161 Risk Ratio (M-H, Fixed, 95% CI) 0.84 [0.73, 0.96]
2 Number of Fatal CHD Events 7 17619 Risk Ratio (M-H, Fixed, 95% CI) 0.78 [0.59, 1.04]
3 Number of Non-fatal CHD
Events
7 4927 Risk Ratio (M-H, Fixed, 95% CI) 0.74 [0.50, 1.10]
4 Total Number of CHD Events 10 27969 Risk Ratio (M-H, Fixed, 95% CI) 0.72 [0.65, 0.79]
5 Number of Fatal CVD Events 2 7459 Risk Ratio (M-H, Fixed, 95% CI) 0.70 [0.50, 0.99]
6 Number of Non-fatal CVD
Events
1 864 Risk Ratio (M-H, Fixed, 95% CI) 0.85 [0.46, 1.58]
7 Total Number of CVD Events 6 12286 Risk Ratio (M-H, Fixed, 95% CI) 0.74 [0.66, 0.85]
8 Number of Fatal Stroke Events 1 6595 Risk Ratio (M-H, Fixed, 95% CI) 1.50 [0.42, 5.30]
9 Number of Non-fatal Stroke
Events
1 255 Risk Ratio (M-H, Fixed, 95% CI) 2.98 [0.12, 72.39]
10 Total Number of Stroke Events 7 21556 Risk Ratio (M-H, Fixed, 95% CI) 0.78 [0.65, 0.94]
11 Total Number of Fatal and
Non-fatal CHD, CVD and
Stroke Events
3 17452 Risk Ratio (M-H, Fixed, 95% CI) 0.70 [0.61, 0.79]
Comparison 3. Lipids
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Total Cholesterol 11 15357 Mean Difference (IV, Random, 95% CI) -0.89 [-1.20, -0.57]
2 LDL Cholesterol 13 22413 Mean Difference (IV, Random, 95% CI) -0.92 [-1.10, -0.74]
Comparison 4. Treatment Compliance
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Treatment Compliance 4 14490 Risk Ratio (M-H, Random, 95% CI) 1.06 [0.99, 1.14]
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Comparison 5. Sensitivity Analysis
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Randomisation for Total
Mortality
7 27242 Risk Ratio (M-H, Fixed, 95% CI) 0.84 [0.74, 0.97]
1.1 Randomisation method
known
4 10723 Risk Ratio (M-H, Fixed, 95% CI) 0.78 [0.65, 0.95]
1.2 Randomisation method
not known
3 16519 Risk Ratio (M-H, Fixed, 95% CI) 0.92 [0.75, 1.12]
2 Randomisation for Fatal CHD
Events
6 16700 Risk Ratio (M-H, Fixed, 95% CI) 0.81 [0.61, 1.08]
2.1 Randomisation method
known
4 8190 Risk Ratio (M-H, Fixed, 95% CI) 0.71 [0.50, 1.02]
2.2 Randomisation method
not known
2 8510 Risk Ratio (M-H, Fixed, 95% CI) 1.02 [0.64, 1.63]
3 Randomisation for Non-fatal
CHD Events
4 3500 Risk Ratio (M-H, Fixed, 95% CI) 0.73 [0.47, 1.14]
3.1 Randomisation method
known
3 1595 Risk Ratio (M-H, Fixed, 95% CI) 0.58 [0.30, 1.12]
3.2 Randomisation method
not known
1 1905 Risk Ratio (M-H, Fixed, 95% CI) 0.90 [0.49, 1.63]
4 Randomisation for Fatal CVD
Events
2 7459 Risk Ratio (M-H, Fixed, 95% CI) 0.70 [0.50, 0.99]
4.1 Randomisation method
known
2 7459 Risk Ratio (M-H, Fixed, 95% CI) 0.70 [0.50, 0.99]
5 Randomisation for Non-fatal
CVD Events
1 864 Risk Ratio (M-H, Fixed, 95% CI) 0.85 [0.46, 1.58]
5.1 Randomisation method
known
1 864 Risk Ratio (M-H, Fixed, 95% CI) 0.85 [0.46, 1.58]
6 Randomisation for Fatal Stroke
Events
1 6595 Risk Ratio (M-H, Fixed, 95% CI) 1.50 [0.42, 5.30]
6.1 Randomisation method
known
1 6595 Risk Ratio (M-H, Fixed, 95% CI) 1.50 [0.42, 5.30]
7 Randomisation for total number
of fatal and non-fatal CHD,
CVD and Stroke Events
3 17359 Risk Ratio (M-H, Fixed, 95% CI) 0.69 [0.61, 0.78]
7.1 Randomisation method
known
1 2838 Risk Ratio (M-H, Fixed, 95% CI) 0.70 [0.57, 0.86]
7.2 Randomisation method
not known
2 14521 Risk Ratio (M-H, Fixed, 95% CI) 0.68 [0.58, 0.80]
8 Study Size for Total Mortality 7 27242 Risk Ratio (M-H, Fixed, 95% CI) 0.84 [0.74, 0.97]
8.1 Over 1000 participants 5 25952 Risk Ratio (M-H, Fixed, 95% CI) 0.84 [0.73, 0.96]
8.2 Under 1000 participants 2 1290 Risk Ratio (M-H, Fixed, 95% CI) 1.07 [0.51, 2.26]
9 Study Size for Fatal CHD Events 6 16700 Risk Ratio (M-H, Fixed, 95% CI) 0.81 [0.61, 1.08]
9.1 Over 1000 participants 3 15105 Risk Ratio (M-H, Fixed, 95% CI) 0.84 [0.62, 1.15]
9.2 Under 1000 participants 3 1595 Risk Ratio (M-H, Fixed, 95% CI) 0.67 [0.33, 1.37]
10 Study Size for Non-fatal CHD
Events
4 3500 Risk Ratio (M-H, Fixed, 95% CI) 0.73 [0.47, 1.14]
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10.1 Over 1000 participants 1 1905 Risk Ratio (M-H, Fixed, 95% CI) 0.90 [0.49, 1.63]
10.2 Under 1000 participants 3 1595 Risk Ratio (M-H, Fixed, 95% CI) 0.58 [0.30, 1.12]
11 Study Size for Fatal CVD
Events
2 7459 Risk Ratio (M-H, Fixed, 95% CI) 0.70 [0.50, 0.99]
11.1 Over 1000 participants 1 6595 Risk Ratio (M-H, Fixed, 95% CI) 0.68 [0.48, 0.98]
11.2 Under 1000 participants 1 864 Risk Ratio (M-H, Fixed, 95% CI) 1.00 [0.25, 3.95]
12 Study Size for Non-fatal CVD
Events
1 864 Risk Ratio (M-H, Fixed, 95% CI) 0.85 [0.46, 1.58]
12.1 Under 1000 participants 1 864 Risk Ratio (M-H, Fixed, 95% CI) 0.85 [0.46, 1.58]
13 Study Size for Fatal Stroke
Events
1 6595 Risk Ratio (M-H, Fixed, 95% CI) 1.50 [0.42, 5.30]
13.1 Over 1000 participants 1 6595 Risk Ratio (M-H, Fixed, 95% CI) 1.50 [0.42, 5.30]
14 Study Size for total number
of fatal and non-fatal CHD,
CVD and stroke events
3 17452 Risk Ratio (M-H, Fixed, 95% CI) 0.70 [0.61, 0.79]
14.1 Over 1000 participants 3 17452 Risk Ratio (M-H, Fixed, 95% CI) 0.70 [0.61, 0.79]
Analysis 1.1. Comparison 1 Adverse Events, Outcome 1 Number of study participants that had Adverse
Events.
Review: Statins for the primary prevention of cardiovascular disease
Comparison: 1 Adverse Events
Outcome: 1 Number of study participants that had Adverse Events
Study or subgroup Statin Therapy Group Usual Care or Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Adult Japanese MEGA Study 396/3958 425/4051 24.7 % 0.95 [ 0.84, 1.09 ]
AFCAPS/TexCAPS 1998 1131/3304 1126/3301 66.3 % 1.00 [ 0.94, 1.07 ]
CAIUS 1996 15/151 14/154 0.8 % 1.09 [ 0.55, 2.18 ]
CARDS 2004 19/1428 20/1410 1.2 % 0.94 [ 0.50, 1.75 ]
KAPS 1995 107/214 95/212 5.6 % 1.12 [ 0.91, 1.36 ]
PHYLLIS A 2004 1/126 0/127 0.0 % 3.02 [ 0.12, 73.53 ]
PHYLLIS B 2004 0/128 1/127 0.1 % 0.33 [ 0.01, 8.04 ]
PREVEND IT 2004 13/433 22/431 1.3 % 0.59 [ 0.30, 1.15 ]
Total (95% CI) 9742 9813 100.0 % 0.99 [ 0.94, 1.05 ]
Total events: 1682 (Statin Therapy Group), 1703 (Usual Care or Placebo)
Heterogeneity: Chi2 = 5.14, df = 7 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 0.27 (P = 0.78)
Test for subgroup differences: Not applicable
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Analysis 1.2. Comparison 1 Adverse Events, Outcome 2 Number of Study Participants that Stopped
Treatment Due to Adverse Events.
Review: Statins for the primary prevention of cardiovascular disease
Comparison: 1 Adverse Events
Outcome: 2 Number of Study Participants that Stopped Treatment Due to Adverse Events
Study or subgroup Statin Therapy Group Usual Care or Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
AFCAPS/TexCAPS 1998 449/3304 445/3301 36.1 % 1.01 [ 0.89, 1.14 ]
CARDS 2004 122/1428 145/1410 19.9 % 0.83 [ 0.66, 1.04 ]
KAPS 1995 8/214 12/212 2.1 % 0.66 [ 0.28, 1.58 ]
PREVEND IT 2004 23/433 33/431 5.6 % 0.69 [ 0.41, 1.16 ]
WOSCOPS 1997 471/3302 432/3293 36.2 % 1.09 [ 0.96, 1.23 ]
Total (95% CI) 8681 8647 100.0 % 0.97 [ 0.85, 1.10 ]
Total events: 1073 (Statin Therapy Group), 1067 (Usual Care or Placebo)
Heterogeneity: Tau2 = 0.01; Chi2 = 7.15, df = 4 (P = 0.13); I2 =44%
Test for overall effect: Z = 0.50 (P = 0.62)
Test for subgroup differences: Not applicable
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Analysis 1.3. Comparison 1 Adverse Events, Outcome 3 Number of Study Participants that were admitted
to Hospital.
Review: Statins for the primary prevention of cardiovascular disease
Comparison: 1 Adverse Events
Outcome: 3 Number of Study Participants that were admitted to Hospital
Study or subgroup Statin Therapy Group Usual Care or Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
ASPEN 2006 65/959 62/946 100.0 % 1.03 [ 0.74, 1.45 ]
Total (95% CI) 959 946 100.0 % 1.03 [ 0.74, 1.45 ]
Total events: 65 (Statin Therapy Group), 62 (Usual Care or Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.20 (P = 0.84)
Test for subgroup differences: Not applicable
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Analysis 1.4. Comparison 1 Adverse Events, Outcome 4 Number of Study Participants underwent
revascularisation.
Review: Statins for the primary prevention of cardiovascular disease
Comparison: 1 Adverse Events
Outcome: 4 Number of Study Participants underwent revascularisation
Study or subgroup Statin Therapy Group Usual Care or Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Adult Japanese MEGA Study 42/3958 68/4051 35.6 % 0.63 [ 0.43, 0.93 ]
CAIUS 1996 3/151 2/154 1.1 % 1.53 [ 0.26, 9.03 ]
CARDS 2004 24/1428 34/1410 18.1 % 0.70 [ 0.42, 1.17 ]
KAPS 1995 4/214 5/212 2.7 % 0.79 [ 0.22, 2.91 ]
WOSCOPS 1997 51/3302 80/3293 42.5 % 0.64 [ 0.45, 0.90 ]
Total (95% CI) 9053 9120 100.0 % 0.66 [ 0.53, 0.83 ]
Total events: 124 (Statin Therapy Group), 189 (Usual Care or Placebo)
Heterogeneity: Chi2 = 1.07, df = 4 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 3.64 (P = 0.00028)
Test for subgroup differences: Not applicable
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Analysis 1.5. Comparison 1 Adverse Events, Outcome 5 Number of Study Participants who developed
cancer.
Review: Statins for the primary prevention of cardiovascular disease
Comparison: 1 Adverse Events
Outcome: 5 Number of Study Participants who developed cancer
Study or subgroup Statin Therapy Group Usual Care or Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
AFCAPS/TexCAPS 1998 252/3304 259/3301 64.3 % 0.97 [ 0.82, 1.15 ]
CAIUS 1996 3/151 4/154 1.0 % 0.76 [ 0.17, 3.36 ]
CARDS 2004 20/1428 30/1410 7.5 % 0.66 [ 0.38, 1.15 ]
KAPS 1995 0/214 1/212 0.4 % 0.33 [ 0.01, 8.06 ]
PHYLLIS A 2004 1/126 0/127 0.1 % 3.02 [ 0.12, 73.53 ]
PHYLLIS B 2004 0/128 1/127 0.4 % 0.33 [ 0.01, 8.04 ]
WOSCOPS 1997 116/3302 106/3293 26.3 % 1.09 [ 0.84, 1.41 ]
Total (95% CI) 8653 8624 100.0 % 0.98 [ 0.85, 1.12 ]
Total events: 392 (Statin Therapy Group), 401 (Usual Care or Placebo)
Heterogeneity: Chi2 = 4.08, df = 6 (P = 0.67); I2 =0.0%
Test for overall effect: Z = 0.36 (P = 0.72)
Test for subgroup differences: Not applicable
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Analysis 1.6. Comparison 1 Adverse Events, Outcome 6 Number of Study Participants who develop
Myalgia or muscle pain.
Review: Statins for the primary prevention of cardiovascular disease
Comparison: 1 Adverse Events
Outcome: 6 Number of Study Participants who develop Myalgia or muscle pain
Study or subgroup Statin Therapy Group Usual Care or Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
AFCAPS/TexCAPS 1998 11/3304 11/3301 4.5 % 1.00 [ 0.43, 2.30 ]
CARDS 2004 61/1428 72/1410 29.4 % 0.84 [ 0.60, 1.17 ]
KAPS 1995 48/214 42/212 17.1 % 1.13 [ 0.78, 1.64 ]
WOSCOPS 1997 117/3302 121/3293 49.1 % 0.96 [ 0.75, 1.24 ]
Total (95% CI) 8248 8216 100.0 % 0.96 [ 0.81, 1.14 ]
Total events: 237 (Statin Therapy Group), 246 (Usual Care or Placebo)
Heterogeneity: Chi2 = 1.44, df = 3 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 0.50 (P = 0.62)
Test for subgroup differences: Not applicable
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Analysis 1.7. Comparison 1 Adverse Events, Outcome 7 Number of Study Participants who develop
Rhabdomyolysis.
Review: Statins for the primary prevention of cardiovascular disease
Comparison: 1 Adverse Events
Outcome: 7 Number of Study Participants who develop Rhabdomyolysis
Study or subgroup Statin Therapy Group Usual Care or Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
AFCAPS/TexCAPS 1998 1/3304 3/3301 100.0 % 0.33 [ 0.03, 3.20 ]
Total (95% CI) 3304 3301 100.0 % 0.33 [ 0.03, 3.20 ]
Total events: 1 (Statin Therapy Group), 3 (Usual Care or Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.95 (P = 0.34)
Test for subgroup differences: Not applicable
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Analysis 1.8. Comparison 1 Adverse Events, Outcome 8 Number of Study Participants who had elevated
Liver Enzymes.
Review: Statins for the primary prevention of cardiovascular disease
Comparison: 1 Adverse Events
Outcome: 8 Number of Study Participants who had elevated Liver Enzymes
Study or subgroup Statin Therapy Group Usual Care or Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
AFCAPS/TexCAPS 1998 18/3304 11/3301 91.6 % 1.63 [ 0.77, 3.46 ]
KAPS 1995 1/214 1/212 8.4 % 0.99 [ 0.06, 15.74 ]
Total (95% CI) 3518 3513 100.0 % 1.58 [ 0.77, 3.25 ]
Total events: 19 (Statin Therapy Group), 12 (Usual Care or Placebo)
Heterogeneity: Chi2 = 0.12, df = 1 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 1.24 (P = 0.21)
Test for subgroup differences: Not applicable
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Analysis 1.9. Comparison 1 Adverse Events, Outcome 9 Number of Study Participants that developed
Prostate Cancer.
Review: Statins for the primary prevention of cardiovascular disease
Comparison: 1 Adverse Events
Outcome: 9 Number of Study Participants that developed Prostate Cancer
Study or subgroup Statin Therapy Group Usual Care or Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
AFCAPS/TexCAPS 1998 109/3304 108/3301 100.0 % 1.01 [ 0.78, 1.31 ]
Total (95% CI) 3304 3301 100.0 % 1.01 [ 0.78, 1.31 ]
Total events: 109 (Statin Therapy Group), 108 (Usual Care or Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.06 (P = 0.95)
Test for subgroup differences: Not applicable
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Analysis 1.10. Comparison 1 Adverse Events, Outcome 10 Number of Study Participants who developed
Melanoma.
Review: Statins for the primary prevention of cardiovascular disease
Comparison: 1 Adverse Events
Outcome: 10 Number of Study Participants who developed Melanoma
Study or subgroup Statin Therapy Group Usual Care or Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
AFCAPS/TexCAPS 1998 14/3304 27/3301 45.5 % 0.52 [ 0.27, 0.99 ]
WOSCOPS 1997 31/3302 30/3293 54.5 % 1.03 [ 0.63, 1.70 ]
Total (95% CI) 6606 6594 100.0 % 0.75 [ 0.39, 1.48 ]
Total events: 45 (Statin Therapy Group), 57 (Usual Care or Placebo)
Heterogeneity: Tau2 = 0.15; Chi2 = 2.74, df = 1 (P = 0.10); I2 =63%
Test for overall effect: Z = 0.83 (P = 0.41)
Test for subgroup differences: Not applicable
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Analysis 1.11. Comparison 1 Adverse Events, Outcome 11 Number of Study Participants who developed
Colon Cancer.
Review: Statins for the primary prevention of cardiovascular disease
Comparison: 1 Adverse Events
Outcome: 11 Number of Study Participants who developed Colon Cancer
Study or subgroup Statin Therapy Group Usual Care or Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
AFCAPS/TexCAPS 1998 25/3304 20/3301 100.0 % 1.25 [ 0.70, 2.24 ]
Total (95% CI) 3304 3301 100.0 % 1.25 [ 0.70, 2.24 ]
Total events: 25 (Statin Therapy Group), 20 (Usual Care or Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.74 (P = 0.46)
Test for subgroup differences: Not applicable
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Analysis 1.12. Comparison 1 Adverse Events, Outcome 12 Number of Study Participants who developed
Lung Cancer.
Review: Statins for the primary prevention of cardiovascular disease
Comparison: 1 Adverse Events
Outcome: 12 Number of Study Participants who developed Lung Cancer
Study or subgroup Statin Therapy Group Usual Care or Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
AFCAPS/TexCAPS 1998 22/3304 17/3301 100.0 % 1.29 [ 0.69, 2.43 ]
Total (95% CI) 3304 3301 100.0 % 1.29 [ 0.69, 2.43 ]
Total events: 22 (Statin Therapy Group), 17 (Usual Care or Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.80 (P = 0.42)
Test for subgroup differences: Not applicable
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Analysis 1.13. Comparison 1 Adverse Events, Outcome 13 Number of Study Participants who develop
Lymphoma.
Review: Statins for the primary prevention of cardiovascular disease
Comparison: 1 Adverse Events
Outcome: 13 Number of Study Participants who develop Lymphoma
Study or subgroup Statin Therapy Group Usual Care or Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
AFCAPS/TexCAPS 1998 12/3304 11/3301 100.0 % 1.09 [ 0.48, 2.47 ]
Total (95% CI) 3304 3301 100.0 % 1.09 [ 0.48, 2.47 ]
Total events: 12 (Statin Therapy Group), 11 (Usual Care or Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.21 (P = 0.84)
Test for subgroup differences: Not applicable
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Analysis 1.14. Comparison 1 Adverse Events, Outcome 14 Number of Study Participants who develop
Bladder Cancer.
Review: Statins for the primary prevention of cardiovascular disease
Comparison: 1 Adverse Events
Outcome: 14 Number of Study Participants who develop Bladder Cancer
Study or subgroup Statin Therapy Group Usual Care or Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
AFCAPS/TexCAPS 1998 12/3304 11/3301 100.0 % 1.09 [ 0.48, 2.47 ]
Total (95% CI) 3304 3301 100.0 % 1.09 [ 0.48, 2.47 ]
Total events: 12 (Statin Therapy Group), 11 (Usual Care or Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.21 (P = 0.84)
Test for subgroup differences: Not applicable
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Analysis 1.15. Comparison 1 Adverse Events, Outcome 15 Number of Study Participants who develop
Breast Cancer.
Review: Statins for the primary prevention of cardiovascular disease
Comparison: 1 Adverse Events
Outcome: 15 Number of Study Participants who develop Breast Cancer
Study or subgroup Statin Therapy Group Usual Care or Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
AFCAPS/TexCAPS 1998 13/3304 9/3301 100.0 % 1.44 [ 0.62, 3.37 ]
Total (95% CI) 3304 3301 100.0 % 1.44 [ 0.62, 3.37 ]
Total events: 13 (Statin Therapy Group), 9 (Usual Care or Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.85 (P = 0.40)
Test for subgroup differences: Not applicable
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Analysis 1.16. Comparison 1 Adverse Events, Outcome 16 Number who developed Gastro-intestinal
Cancers.
Review: Statins for the primary prevention of cardiovascular disease
Comparison: 1 Adverse Events
Outcome: 16 Number who developed Gastro-intestinal Cancers
Study or subgroup Statin Therapy Group Usual Care or Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
WOSCOPS 1997 32/3302 26/3293 100.0 % 1.23 [ 0.73, 2.05 ]
Total (95% CI) 3302 3293 100.0 % 1.23 [ 0.73, 2.05 ]
Total events: 32 (Statin Therapy Group), 26 (Usual Care or Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.78 (P = 0.44)
Test for subgroup differences: Not applicable
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Analysis 1.17. Comparison 1 Adverse Events, Outcome 17 Number of Study Participants who developed
Genito-urinary tract Cancers.
Review: Statins for the primary prevention of cardiovascular disease
Comparison: 1 Adverse Events
Outcome: 17 Number of Study Participants who developed Genito-urinary tract Cancers
Study or subgroup Statin Therapy Group Usual Care or Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
WOSCOPS 1997 27/3302 28/3293 100.0 % 0.96 [ 0.57, 1.63 ]
Total (95% CI) 3302 3293 100.0 % 0.96 [ 0.57, 1.63 ]
Total events: 27 (Statin Therapy Group), 28 (Usual Care or Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.15 (P = 0.88)
Test for subgroup differences: Not applicable
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Analysis 1.18. Comparison 1 Adverse Events, Outcome 18 Number who developed Respiratory Tract
Cancers.
Review: Statins for the primary prevention of cardiovascular disease
Comparison: 1 Adverse Events
Outcome: 18 Number who developed Respiratory Tract Cancers
Study or subgroup Statin Therapy Group Usual Care or Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
WOSCOPS 1997 26/3302 22/3293 100.0 % 1.18 [ 0.67, 2.08 ]
Total (95% CI) 3302 3293 100.0 % 1.18 [ 0.67, 2.08 ]
Total events: 26 (Statin Therapy Group), 22 (Usual Care or Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.57 (P = 0.57)
Test for subgroup differences: Not applicable
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Analysis 2.1. Comparison 2 Mortality and Morbidity, Outcome 1 Total Mortality.
Review: Statins for the primary prevention of cardiovascular disease
Comparison: 2 Mortality and Morbidity
Outcome: 1 Total Mortality
Study or subgroup Statin Therapy Group Usual Care or Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
ACAPS 1994 0/460 4/459 1.0 % 0.11 [ 0.01, 2.05 ]
Adult Japanese MEGA Study 57/3958 81/4051 18.5 % 0.72 [ 0.51, 1.01 ]
AFCAPS/TexCAPS 1998 80/3304 77/3301 17.8 % 1.04 [ 0.76, 1.41 ]
ASPEN 2006 44/959 40/946 9.3 % 1.09 [ 0.71, 1.65 ]
CARDS 2004 61/1428 82/1410 19.1 % 0.73 [ 0.53, 1.01 ]
KAPS 1995 4/214 5/212 1.2 % 0.79 [ 0.22, 2.91 ]
PREVEND IT 2004 10/433 8/431 1.9 % 1.24 [ 0.50, 3.12 ]
WOSCOPS 1997 106/3302 135/3293 31.2 % 0.78 [ 0.61, 1.01 ]
Total (95% CI) 14058 14103 100.0 % 0.84 [ 0.73, 0.96 ]
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(. . . Continued)
Study or subgroup Statin Therapy Group Usual Care or Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Total events: 362 (Statin Therapy Group), 432 (Usual Care or Placebo)
Heterogeneity: Chi2 = 7.57, df = 7 (P = 0.37); I2 =8%
Test for overall effect: Z = 2.53 (P = 0.011)
Test for subgroup differences: Not applicable
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Analysis 2.2. Comparison 2 Mortality and Morbidity, Outcome 2 Number of Fatal CHD Events.
Review: Statins for the primary prevention of cardiovascular disease
Comparison: 2 Mortality and Morbidity
Outcome: 2 Number of Fatal CHD Events
Study or subgroup Statin Therapy Group Usual Care or Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
ACAPS 1994 0/460 4/459 4.1 % 0.11 [ 0.01, 2.05 ]
AFCAPS/TexCAPS 1998 11/3304 15/3301 13.7 % 0.73 [ 0.34, 1.59 ]
ASPEN 2006 24/959 19/946 17.5 % 1.25 [ 0.69, 2.26 ]
CAIUS 1996 1/151 0/154 0.5 % 3.06 [ 0.13, 74.51 ]
KAPS 1995 2/214 2/212 1.8 % 0.99 [ 0.14, 6.97 ]
PREVEND IT 2004 9/433 16/431 14.7 % 0.56 [ 0.25, 1.25 ]
WOSCOPS 1997 38/3302 52/3293 47.7 % 0.73 [ 0.48, 1.10 ]
Total (95% CI) 8823 8796 100.0 % 0.78 [ 0.59, 1.04 ]
Total events: 85 (Statin Therapy Group), 108 (Usual Care or Placebo)
Heterogeneity: Chi2 = 5.62, df = 6 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 1.69 (P = 0.091)
Test for subgroup differences: Not applicable
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Analysis 2.3. Comparison 2 Mortality and Morbidity, Outcome 3 Number of Non-fatal CHD Events.
Review: Statins for the primary prevention of cardiovascular disease
Comparison: 2 Mortality and Morbidity
Outcome: 3 Number of Non-fatal CHD Events
Study or subgroup Statin Therapy Group Usual Care or Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
ACAPS 1994 5/460 5/459 9.1 % 1.00 [ 0.29, 3.42 ]
ASPEN 2006 20/959 22/946 40.1 % 0.90 [ 0.49, 1.63 ]
CAIUS 1996 2/151 2/154 3.6 % 1.02 [ 0.15, 7.15 ]
KAPS 1995 3/214 6/212 10.9 % 0.50 [ 0.13, 1.95 ]
PHYLLIS A 2004 0/126 3/127 6.3 % 0.14 [ 0.01, 2.76 ]
PHYLLIS B 2004 1/128 0/127 0.9 % 2.98 [ 0.12, 72.39 ]
PREVEND IT 2004 9/433 16/431 29.1 % 0.56 [ 0.25, 1.25 ]
Total (95% CI) 2471 2456 100.0 % 0.74 [ 0.50, 1.10 ]
Total events: 40 (Statin Therapy Group), 54 (Usual Care or Placebo)
Heterogeneity: Chi2 = 3.43, df = 6 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 1.47 (P = 0.14)
Test for subgroup differences: Not applicable
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Analysis 2.4. Comparison 2 Mortality and Morbidity, Outcome 4 Total Number of CHD Events.
Review: Statins for the primary prevention of cardiovascular disease
Comparison: 2 Mortality and Morbidity
Outcome: 4 Total Number of CHD Events
Study or subgroup Statin Therapy Group Usual Care or Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
ACAPS 1994 5/460 9/459 1.0 % 0.55 [ 0.19, 1.64 ]
Adult Japanese MEGA Study 184/3958 280/4051 30.2 % 0.67 [ 0.56, 0.81 ]
AFCAPS/TexCAPS 1998 163/3304 215/3301 23.5 % 0.76 [ 0.62, 0.92 ]
ASPEN 2006 72/959 75/946 8.2 % 0.95 [ 0.69, 1.29 ]
CAIUS 1996 3/151 2/154 0.2 % 1.53 [ 0.26, 9.03 ]
CARDS 2004 51/1428 77/1410 8.4 % 0.65 [ 0.46, 0.92 ]
HYRIM 2004 6/142 9/143 1.0 % 0.67 [ 0.25, 1.84 ]
PHYLLIS A 2004 0/126 3/127 0.4 % 0.14 [ 0.01, 2.76 ]
PHYLLIS B 2004 1/128 0/127 0.1 % 2.98 [ 0.12, 72.39 ]
WOSCOPS 1997 174/3302 248/3293 27.1 % 0.70 [ 0.58, 0.84 ]
Total (95% CI) 13958 14011 100.0 % 0.72 [ 0.65, 0.79 ]
Total events: 659 (Statin Therapy Group), 918 (Usual Care or Placebo)
Heterogeneity: Chi2 = 7.01, df = 9 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 6.61 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 2.5. Comparison 2 Mortality and Morbidity, Outcome 5 Number of Fatal CVD Events.
Review: Statins for the primary prevention of cardiovascular disease
Comparison: 2 Mortality and Morbidity
Outcome: 5 Number of Fatal CVD Events
Study or subgroup Statin Therapy Group Usual Care or Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
PREVEND IT 2004 4/433 4/431 5.2 % 1.00 [ 0.25, 3.95 ]
WOSCOPS 1997 50/3302 73/3293 94.8 % 0.68 [ 0.48, 0.98 ]
Total (95% CI) 3735 3724 100.0 % 0.70 [ 0.50, 0.99 ]
Total events: 54 (Statin Therapy Group), 77 (Usual Care or Placebo)
Heterogeneity: Chi2 = 0.27, df = 1 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 2.03 (P = 0.042)
Test for subgroup differences: Not applicable
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Analysis 2.6. Comparison 2 Mortality and Morbidity, Outcome 6 Number of Non-fatal CVD Events.
Review: Statins for the primary prevention of cardiovascular disease
Comparison: 2 Mortality and Morbidity
Outcome: 6 Number of Non-fatal CVD Events
Study or subgroup Statin Therapy Group Usual Care or Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
PREVEND IT 2004 18/433 21/431 100.0 % 0.85 [ 0.46, 1.58 ]
Total (95% CI) 433 431 100.0 % 0.85 [ 0.46, 1.58 ]
Total events: 18 (Statin Therapy Group), 21 (Usual Care or Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.51 (P = 0.61)
Test for subgroup differences: Not applicable
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Analysis 2.7. Comparison 2 Mortality and Morbidity, Outcome 7 Total Number of CVD Events.
Review: Statins for the primary prevention of cardiovascular disease
Comparison: 2 Mortality and Morbidity
Outcome: 7 Total Number of CVD Events
Study or subgroup Statin Therapy Group Usual Care or Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
CAIUS 1996 3/151 2/154 0.4 % 1.53 [ 0.26, 9.03 ]
HYRIM 2004 11/142 15/143 3.1 % 0.74 [ 0.35, 1.55 ]
MRC/BHF Heart Protection 276/2006 367/1976 76.2 % 0.74 [ 0.64, 0.85 ]
PHYLLIS B 2004 1/128 0/127 0.1 % 2.98 [ 0.12, 72.39 ]
PREVEND IT 2004 22/433 25/431 5.2 % 0.88 [ 0.50, 1.53 ]
WOSCOPS 1997 50/3302 73/3293 15.1 % 0.68 [ 0.48, 0.98 ]
Total (95% CI) 6162 6124 100.0 % 0.74 [ 0.66, 0.85 ]
Total events: 363 (Statin Therapy Group), 482 (Usual Care or Placebo)
Heterogeneity: Chi2 = 1.91, df = 5 (P = 0.86); I2 =0.0%
Test for overall effect: Z = 4.55 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 2.8. Comparison 2 Mortality and Morbidity, Outcome 8 Number of Fatal Stroke Events.
Review: Statins for the primary prevention of cardiovascular disease
Comparison: 2 Mortality and Morbidity
Outcome: 8 Number of Fatal Stroke Events
Study or subgroup Statin Therapy Group Usual Care or Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
WOSCOPS 1997 6/3302 4/3293 100.0 % 1.50 [ 0.42, 5.30 ]
Total (95% CI) 3302 3293 100.0 % 1.50 [ 0.42, 5.30 ]
Total events: 6 (Statin Therapy Group), 4 (Usual Care or Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.62 (P = 0.53)
Test for subgroup differences: Not applicable
0.2 0.5 1 2 5
Favours treatment Favours control
54Statins for the primary prevention of cardiovascular disease (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 2.9. Comparison 2 Mortality and Morbidity, Outcome 9 Number of Non-fatal Stroke Events.
Review: Statins for the primary prevention of cardiovascular disease
Comparison: 2 Mortality and Morbidity
Outcome: 9 Number of Non-fatal Stroke Events
Study or subgroup Statin Therapy Group Usual Care or Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
PHYLLIS B 2004 1/128 0/127 100.0 % 2.98 [ 0.12, 72.39 ]
Total (95% CI) 128 127 100.0 % 2.98 [ 0.12, 72.39 ]
Total events: 1 (Statin Therapy Group), 0 (Usual Care or Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.67 (P = 0.50)
Test for subgroup differences: Not applicable
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Analysis 2.10. Comparison 2 Mortality and Morbidity, Outcome 10 Total Number of Stroke Events.
Review: Statins for the primary prevention of cardiovascular disease
Comparison: 2 Mortality and Morbidity
Outcome: 10 Total Number of Stroke Events
Study or subgroup Statin Therapy Group Usual Care or Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
ACAPS 1994 0/460 5/459 2.2 % 0.09 [ 0.01, 1.64 ]
Adult Japanese MEGA Study 94/3958 120/4051 46.9 % 0.80 [ 0.61, 1.05 ]
ASPEN 2006 27/959 29/946 11.6 % 0.92 [ 0.55, 1.54 ]
CARDS 2004 21/1428 39/1410 15.5 % 0.53 [ 0.31, 0.90 ]
KAPS 1995 2/214 5/212 2.0 % 0.40 [ 0.08, 2.02 ]
PREVEND IT 2004 7/433 4/431 1.6 % 1.74 [ 0.51, 5.91 ]
WOSCOPS 1997 46/3302 51/3293 20.2 % 0.90 [ 0.61, 1.34 ]
Total (95% CI) 10754 10802 100.0 % 0.78 [ 0.65, 0.94 ]
Total events: 197 (Statin Therapy Group), 253 (Usual Care or Placebo)
Heterogeneity: Chi2 = 7.40, df = 6 (P = 0.29); I2 =19%
Test for overall effect: Z = 2.59 (P = 0.0097)
Test for subgroup differences: Not applicable
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Analysis 2.11. Comparison 2 Mortality and Morbidity, Outcome 11 Total Number of Fatal and Non-fatal
CHD, CVD and Stroke Events.
Review: Statins for the primary prevention of cardiovascular disease
Comparison: 2 Mortality and Morbidity
Outcome: 11 Total Number of Fatal and Non-fatal CHD, CVD and Stroke Events
Study or subgroup Statin Therapy Group Usual Care or Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Adult Japanese MEGA Study 134/3958 182/4051 32.5 % 0.75 [ 0.61, 0.94 ]
AFCAPS/TexCAPS 1998 116/3304 183/3301 33.1 % 0.63 [ 0.50, 0.80 ]
CARDS 2004 134/1428 189/1410 34.4 % 0.70 [ 0.57, 0.86 ]
Total (95% CI) 8690 8762 100.0 % 0.70 [ 0.61, 0.79 ]
Total events: 384 (Statin Therapy Group), 554 (Usual Care or Placebo)
Heterogeneity: Chi2 = 1.17, df = 2 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 5.66 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 3.1. Comparison 3 Lipids, Outcome 1 Total Cholesterol.
Review: Statins for the primary prevention of cardiovascular disease
Comparison: 3 Lipids
Outcome: 1 Total Cholesterol
Study or subgroup Statin Therapy Group Usual Care or Placebo Mean Difference Weight Mean Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Adult Japanese MEGA Study 3958 -0.3 (0.31) 4051 -0.05 (0.31) 9.4 % -0.25 [ -0.26, -0.24 ]
ASPEN 2006 959 -0.51 (0.8) 946 -0.04 (0.8) 9.3 % -0.47 [ -0.54, -0.40 ]
CAIUS 1996 151 -1.01 (1.04) 154 0.18 (0.87) 9.0 % -1.19 [ -1.41, -0.97 ]
CARDS 2004 1428 -1.24 (0.84) 1410 -0.07 (0.87) 9.4 % -1.17 [ -1.23, -1.11 ]
CELL A 1996 111 -0.89 (0.86) 117 -0.18 (0.72) 9.0 % -0.71 [ -0.92, -0.50 ]
CELL B 1996 117 -0.86 (2.01) 110 0.07 (0.64) 8.3 % -0.93 [ -1.31, -0.55 ]
Derosa 2003 24 -1.63 (0.51) 23 -0.83 (0.58) 8.6 % -0.80 [ -1.11, -0.49 ]
KAPS 1995 214 -1.5 (0.66) 212 0 (0.66) 9.3 % -1.50 [ -1.63, -1.37 ]
PHYLLIS A 2004 126 -1.07 (0.56) 127 -0.02 (0.41) 9.3 % -1.05 [ -1.17, -0.93 ]
PHYLLIS B 2004 128 -1.13 (0.52) 127 -0.24 (0.47) 9.3 % -0.89 [ -1.01, -0.77 ]
PREVEND IT 2004 433 -1 (1) 431 -0.2 (1.05) 9.2 % -0.80 [ -0.94, -0.66 ]
Total (95% CI) 7649 7708 100.0 % -0.89 [ -1.20, -0.57 ]
Heterogeneity: Tau2 = 0.28; Chi2 = 1521.63, df = 10 (P<0.00001); I2 =99%
Test for overall effect: Z = 5.47 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 3.2. Comparison 3 Lipids, Outcome 2 LDL Cholesterol.
Review: Statins for the primary prevention of cardiovascular disease
Comparison: 3 Lipids
Outcome: 2 LDL Cholesterol
Study or subgroup Statin Therapy Group Usual Care or Placebo Mean Difference Weight Mean Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
ACAPS 1994 231 -1.1 (0.72) 230 -0.2 (0.69) 7.8 % -0.90 [ -1.03, -0.77 ]
Adult Japanese MEGA Study 3958 -0.47 (0.47) 4051 -0.08 (0.48) 8.1 % -0.39 [ -0.41, -0.37 ]
ASPEN 2006 959 -0.79 (0.67) 946 -0.01 (0.67) 8.0 % -0.78 [ -0.84, -0.72 ]
CAIUS 1996 151 -1.03 (0.86) 154 0.09 (0.74) 7.5 % -1.12 [ -1.30, -0.94 ]
CARDS 2004 1428 -0.93 (0.71) 1410 0.1 (0.75) 8.0 % -1.03 [ -1.08, -0.98 ]
CELL A 1996 111 -0.94 (0.89) 117 -0.21 (0.72) 7.3 % -0.73 [ -0.94, -0.52 ]
CELL B 1996 117 -0.96 (0.8) 110 -0.04 (0.64) 7.4 % -0.92 [ -1.11, -0.73 ]
Derosa 2003 24 -1.61 (0.57) 23 -0.61 (0.53) 6.5 % -1.00 [ -1.31, -0.69 ]
KAPS 1995 214 -1.4 (0.63) 212 0.2 (0.66) 7.8 % -1.60 [ -1.72, -1.48 ]
PHYLLIS A 2004 126 -1.03 (0.57) 127 -0.05 (0.44) 7.8 % -0.98 [ -1.11, -0.85 ]
PHYLLIS B 2004 128 -1.16 (0.47) 127 -0.25 (0.43) 7.9 % -0.91 [ -1.02, -0.80 ]
PREVEND IT 2004 433 -1 (0.95) 431 -0.1 (0.95) 7.8 % -0.90 [ -1.03, -0.77 ]
WOSCOPS 1997 3302 -0.7 (0.71) 3293 0 (0.71) 8.1 % -0.70 [ -0.73, -0.67 ]
Total (95% CI) 11182 11231 100.0 % -0.92 [ -1.10, -0.74 ]
Heterogeneity: Tau2 = 0.11; Chi2 = 1118.47, df = 12 (P<0.00001); I2 =99%
Test for overall effect: Z = 9.90 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 4.1. Comparison 4 Treatment Compliance, Outcome 1 Treatment Compliance.
Review: Statins for the primary prevention of cardiovascular disease
Comparison: 4 Treatment Compliance
Outcome: 1 Treatment Compliance
Study or subgroup Statin Therapy Group Usual Care or Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
AFCAPS/TexCAPS 1998 2335/3304 2081/3301 27.6 % 1.12 [ 1.08, 1.16 ]
KAPS 1995 197/214 192/212 24.4 % 1.02 [ 0.96, 1.08 ]
PREVEND IT 2004 321/433 286/431 20.1 % 1.12 [ 1.02, 1.22 ]
WOSCOPS 1997 2311/3302 2305/3293 27.9 % 1.00 [ 0.97, 1.03 ]
Total (95% CI) 7253 7237 100.0 % 1.06 [ 0.99, 1.14 ]
Total events: 5164 (Statin Therapy Group), 4864 (Usual Care or Placebo)
Heterogeneity: Tau2 = 0.00; Chi2 = 26.73, df = 3 (P<0.00001); I2 =89%
Test for overall effect: Z = 1.64 (P = 0.10)
Test for subgroup differences: Not applicable
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Analysis 5.1. Comparison 5 Sensitivity Analysis, Outcome 1 Randomisation for Total Mortality.
Review: Statins for the primary prevention of cardiovascular disease
Comparison: 5 Sensitivity Analysis
Outcome: 1 Randomisation for Total Mortality
Study or subgroup Statin Therapy Group Usual Care or Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Randomisation method known
CARDS 2004 61/1428 82/1410 19.3 % 0.73 [ 0.53, 1.01 ]
KAPS 1995 4/214 5/212 1.2 % 0.79 [ 0.22, 2.91 ]
PREVEND IT 2004 10/433 8/431 1.9 % 1.24 [ 0.50, 3.12 ]
WOSCOPS 1997 106/3302 135/3293 31.6 % 0.78 [ 0.61, 1.01 ]
Subtotal (95% CI) 5377 5346 53.9 % 0.78 [ 0.65, 0.95 ]
Total events: 181 (Statin Therapy Group), 230 (Usual Care or Placebo)
Heterogeneity: Chi2 = 1.12, df = 3 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 2.53 (P = 0.012)
2 Randomisation method not known
Adult Japanese MEGA Study 57/3958 81/4051 18.7 % 0.72 [ 0.51, 1.01 ]
AFCAPS/TexCAPS 1998 80/3304 77/3301 18.0 % 1.04 [ 0.76, 1.41 ]
ASPEN 2006 44/959 40/946 9.4 % 1.09 [ 0.71, 1.65 ]
Subtotal (95% CI) 8221 8298 46.1 % 0.92 [ 0.75, 1.12 ]
Total events: 181 (Statin Therapy Group), 198 (Usual Care or Placebo)
Heterogeneity: Chi2 = 3.22, df = 2 (P = 0.20); I2 =38%
Test for overall effect: Z = 0.83 (P = 0.40)
Total (95% CI) 13598 13644 100.0 % 0.84 [ 0.74, 0.97 ]
Total events: 362 (Statin Therapy Group), 428 (Usual Care or Placebo)
Heterogeneity: Chi2 = 5.71, df = 6 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 2.40 (P = 0.016)
Test for subgroup differences: Chi2 = 1.31, df = 1 (P = 0.25), I2 =24%
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Analysis 5.2. Comparison 5 Sensitivity Analysis, Outcome 2 Randomisation for Fatal CHD Events.
Review: Statins for the primary prevention of cardiovascular disease
Comparison: 5 Sensitivity Analysis
Outcome: 2 Randomisation for Fatal CHD Events
Study or subgroup Statin Therapy Group Usual Care or Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Randomisation method known
CAIUS 1996 1/151 0/154 0.5 % 3.06 [ 0.13, 74.51 ]
KAPS 1995 2/214 2/212 1.9 % 0.99 [ 0.14, 6.97 ]
PREVEND IT 2004 9/433 16/431 15.3 % 0.56 [ 0.25, 1.25 ]
WOSCOPS 1997 38/3302 52/3293 49.7 % 0.73 [ 0.48, 1.10 ]
Subtotal (95% CI) 4100 4090 67.4 % 0.71 [ 0.50, 1.02 ]
Total events: 50 (Statin Therapy Group), 70 (Usual Care or Placebo)
Heterogeneity: Chi2 = 1.27, df = 3 (P = 0.74); I2 =0.0%
Test for overall effect: Z = 1.84 (P = 0.066)
2 Randomisation method not known
AFCAPS/TexCAPS 1998 11/3304 15/3301 14.3 % 0.73 [ 0.34, 1.59 ]
ASPEN 2006 24/959 19/946 18.3 % 1.25 [ 0.69, 2.26 ]
Subtotal (95% CI) 4263 4247 32.6 % 1.02 [ 0.64, 1.63 ]
Total events: 35 (Statin Therapy Group), 34 (Usual Care or Placebo)
Heterogeneity: Chi2 = 1.13, df = 1 (P = 0.29); I2 =12%
Test for overall effect: Z = 0.08 (P = 0.93)
Total (95% CI) 8363 8337 100.0 % 0.81 [ 0.61, 1.08 ]
Total events: 85 (Statin Therapy Group), 104 (Usual Care or Placebo)
Heterogeneity: Chi2 = 3.84, df = 5 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 1.42 (P = 0.15)
Test for subgroup differences: Chi2 = 1.40, df = 1 (P = 0.24), I2 =29%
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Analysis 5.3. Comparison 5 Sensitivity Analysis, Outcome 3 Randomisation for Non-fatal CHD Events.
Review: Statins for the primary prevention of cardiovascular disease
Comparison: 5 Sensitivity Analysis
Outcome: 3 Randomisation for Non-fatal CHD Events
Study or subgroup Statin Therapy Group Usual Care or Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Randomisation method known
CAIUS 1996 2/151 2/154 4.3 % 1.02 [ 0.15, 7.15 ]
KAPS 1995 3/214 6/212 13.0 % 0.50 [ 0.13, 1.95 ]
PREVEND IT 2004 9/433 16/431 34.7 % 0.56 [ 0.25, 1.25 ]
Subtotal (95% CI) 798 797 52.1 % 0.58 [ 0.30, 1.12 ]
Total events: 14 (Statin Therapy Group), 24 (Usual Care or Placebo)
Heterogeneity: Chi2 = 0.38, df = 2 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 1.63 (P = 0.10)
2 Randomisation method not known
ASPEN 2006 20/959 22/946 47.9 % 0.90 [ 0.49, 1.63 ]
Subtotal (95% CI) 959 946 47.9 % 0.90 [ 0.49, 1.63 ]
Total events: 20 (Statin Therapy Group), 22 (Usual Care or Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.36 (P = 0.72)
Total (95% CI) 1757 1743 100.0 % 0.73 [ 0.47, 1.14 ]
Total events: 34 (Statin Therapy Group), 46 (Usual Care or Placebo)
Heterogeneity: Chi2 = 1.29, df = 3 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 1.39 (P = 0.16)
Test for subgroup differences: Chi2 = 0.92, df = 1 (P = 0.34), I2 =0.0%
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Analysis 5.4. Comparison 5 Sensitivity Analysis, Outcome 4 Randomisation for Fatal CVD Events.
Review: Statins for the primary prevention of cardiovascular disease
Comparison: 5 Sensitivity Analysis
Outcome: 4 Randomisation for Fatal CVD Events
Study or subgroup Statin Therapy Group Usual Care or Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Randomisation method known
PREVEND IT 2004 4/433 4/431 5.2 % 1.00 [ 0.25, 3.95 ]
WOSCOPS 1997 50/3302 73/3293 94.8 % 0.68 [ 0.48, 0.98 ]
Total (95% CI) 3735 3724 100.0 % 0.70 [ 0.50, 0.99 ]
Total events: 54 (Statin Therapy Group), 77 (Usual Care or Placebo)
Heterogeneity: Chi2 = 0.27, df = 1 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 2.03 (P = 0.042)
Test for subgroup differences: Not applicable
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Analysis 5.5. Comparison 5 Sensitivity Analysis, Outcome 5 Randomisation for Non-fatal CVD Events.
Review: Statins for the primary prevention of cardiovascular disease
Comparison: 5 Sensitivity Analysis
Outcome: 5 Randomisation for Non-fatal CVD Events
Study or subgroup Statin Therapy Group Usual Care or Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Randomisation method known
PREVEND IT 2004 18/433 21/431 100.0 % 0.85 [ 0.46, 1.58 ]
Total (95% CI) 433 431 100.0 % 0.85 [ 0.46, 1.58 ]
Total events: 18 (Statin Therapy Group), 21 (Usual Care or Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.51 (P = 0.61)
Test for subgroup differences: Not applicable
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Analysis 5.6. Comparison 5 Sensitivity Analysis, Outcome 6 Randomisation for Fatal Stroke Events.
Review: Statins for the primary prevention of cardiovascular disease
Comparison: 5 Sensitivity Analysis
Outcome: 6 Randomisation for Fatal Stroke Events
Study or subgroup Statin Therapy Group Usual Care or Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Randomisation method known
WOSCOPS 1997 6/3302 4/3293 100.0 % 1.50 [ 0.42, 5.30 ]
Total (95% CI) 3302 3293 100.0 % 1.50 [ 0.42, 5.30 ]
Total events: 6 (Statin Therapy Group), 4 (Usual Care or Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.62 (P = 0.53)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours experimental Favours control
Analysis 5.7. Comparison 5 Sensitivity Analysis, Outcome 7 Randomisation for total number of fatal and
non-fatal CHD, CVD and Stroke Events.
Review: Statins for the primary prevention of cardiovascular disease
Comparison: 5 Sensitivity Analysis
Outcome: 7 Randomisation for total number of fatal and non-fatal CHD, CVD and Stroke Events
Study or subgroup Statin Therapy Group Usual Care or Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Randomisation method known
CARDS 2004 134/1428 189/1410 34.3 % 0.70 [ 0.57, 0.86 ]
Subtotal (95% CI) 1428 1410 34.3 % 0.70 [ 0.57, 0.86 ]
Total events: 134 (Statin Therapy Group), 189 (Usual Care or Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 3.35 (P = 0.00081)
2 Randomisation method not known
Adult Japanese MEGA Study 134/3958 182/3958 32.8 % 0.74 [ 0.59, 0.92 ]
AFCAPS/TexCAPS 1998 116/3304 183/3301 33.0 % 0.63 [ 0.50, 0.80 ]
Subtotal (95% CI) 7262 7259 65.7 % 0.68 [ 0.58, 0.80 ]
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(. . . Continued)
Study or subgroup Statin Therapy Group Usual Care or Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Total events: 250 (Statin Therapy Group), 365 (Usual Care or Placebo)
Heterogeneity: Chi2 = 0.88, df = 1 (P = 0.35); I2 =0.0%
Test for overall effect: Z = 4.71 (P < 0.00001)
Total (95% CI) 8690 8669 100.0 % 0.69 [ 0.61, 0.78 ]
Total events: 384 (Statin Therapy Group), 554 (Usual Care or Placebo)
Heterogeneity: Chi2 = 0.90, df = 2 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 5.78 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.03, df = 1 (P = 0.87), I2 =0.0%
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Analysis 5.8. Comparison 5 Sensitivity Analysis, Outcome 8 Study Size for Total Mortality.
Review: Statins for the primary prevention of cardiovascular disease
Comparison: 5 Sensitivity Analysis
Outcome: 8 Study Size for Total Mortality
Study or subgroup Statin Therapy Group Usual Care or Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Over 1000 participants
Adult Japanese MEGA Study 57/3958 81/4051 18.7 % 0.72 [ 0.51, 1.01 ]
AFCAPS/TexCAPS 1998 80/3304 77/3301 18.0 % 1.04 [ 0.76, 1.41 ]
ASPEN 2006 44/959 40/946 9.4 % 1.09 [ 0.71, 1.65 ]
CARDS 2004 61/1428 82/1410 19.3 % 0.73 [ 0.53, 1.01 ]
WOSCOPS 1997 106/3302 135/3293 31.6 % 0.78 [ 0.61, 1.01 ]
Subtotal (95% CI) 12951 13001 97.0 % 0.84 [ 0.73, 0.96 ]
Total events: 348 (Statin Therapy Group), 415 (Usual Care or Placebo)
Heterogeneity: Chi2 = 5.01, df = 4 (P = 0.29); I2 =20%
Test for overall effect: Z = 2.47 (P = 0.013)
2 Under 1000 participants
KAPS 1995 4/214 5/212 1.2 % 0.79 [ 0.22, 2.91 ]
PREVEND IT 2004 10/433 8/431 1.9 % 1.24 [ 0.50, 3.12 ]
Subtotal (95% CI) 647 643 3.0 % 1.07 [ 0.51, 2.26 ]
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(. . . Continued)
Study or subgroup Statin Therapy Group Usual Care or Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Total events: 14 (Statin Therapy Group), 13 (Usual Care or Placebo)
Heterogeneity: Chi2 = 0.31, df = 1 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 0.18 (P = 0.86)
Total (95% CI) 13598 13644 100.0 % 0.84 [ 0.74, 0.97 ]
Total events: 362 (Statin Therapy Group), 428 (Usual Care or Placebo)
Heterogeneity: Chi2 = 5.71, df = 6 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 2.40 (P = 0.016)
Test for subgroup differences: Chi2 = 0.40, df = 1 (P = 0.53), I2 =0.0%
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Analysis 5.9. Comparison 5 Sensitivity Analysis, Outcome 9 Study Size for Fatal CHD Events.
Review: Statins for the primary prevention of cardiovascular disease
Comparison: 5 Sensitivity Analysis
Outcome: 9 Study Size for Fatal CHD Events
Study or subgroup Statin Therapy Group Usual Care or Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Over 1000 participants
AFCAPS/TexCAPS 1998 11/3304 15/3301 14.3 % 0.73 [ 0.34, 1.59 ]
ASPEN 2006 24/959 19/946 18.3 % 1.25 [ 0.69, 2.26 ]
WOSCOPS 1997 38/3302 52/3293 49.7 % 0.73 [ 0.48, 1.10 ]
Subtotal (95% CI) 7565 7540 82.3 % 0.84 [ 0.62, 1.15 ]
Total events: 73 (Statin Therapy Group), 86 (Usual Care or Placebo)
Heterogeneity: Chi2 = 2.25, df = 2 (P = 0.32); I2 =11%
Test for overall effect: Z = 1.07 (P = 0.28)
2 Under 1000 participants
CAIUS 1996 1/151 0/154 0.5 % 3.06 [ 0.13, 74.51 ]
KAPS 1995 2/214 2/212 1.9 % 0.99 [ 0.14, 6.97 ]
PREVEND IT 2004 9/433 16/431 15.3 % 0.56 [ 0.25, 1.25 ]
Subtotal (95% CI) 798 797 17.7 % 0.67 [ 0.33, 1.37 ]
Total events: 12 (Statin Therapy Group), 18 (Usual Care or Placebo)
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(. . . Continued)
Study or subgroup Statin Therapy Group Usual Care or Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Heterogeneity: Chi2 = 1.22, df = 2 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 1.09 (P = 0.27)
Total (95% CI) 8363 8337 100.0 % 0.81 [ 0.61, 1.08 ]
Total events: 85 (Statin Therapy Group), 104 (Usual Care or Placebo)
Heterogeneity: Chi2 = 3.84, df = 5 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 1.42 (P = 0.15)
Test for subgroup differences: Chi2 = 0.33, df = 1 (P = 0.57), I2 =0.0%
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Analysis 5.10. Comparison 5 Sensitivity Analysis, Outcome 10 Study Size for Non-fatal CHD Events.
Review: Statins for the primary prevention of cardiovascular disease
Comparison: 5 Sensitivity Analysis
Outcome: 10 Study Size for Non-fatal CHD Events
Study or subgroup Statin Therapy Group Usual Care or Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Over 1000 participants
ASPEN 2006 20/959 22/946 47.9 % 0.90 [ 0.49, 1.63 ]
Subtotal (95% CI) 959 946 47.9 % 0.90 [ 0.49, 1.63 ]
Total events: 20 (Statin Therapy Group), 22 (Usual Care or Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.36 (P = 0.72)
2 Under 1000 participants
CAIUS 1996 2/151 2/154 4.3 % 1.02 [ 0.15, 7.15 ]
KAPS 1995 3/214 6/212 13.0 % 0.50 [ 0.13, 1.95 ]
PREVEND IT 2004 9/433 16/431 34.7 % 0.56 [ 0.25, 1.25 ]
Subtotal (95% CI) 798 797 52.1 % 0.58 [ 0.30, 1.12 ]
Total events: 14 (Statin Therapy Group), 24 (Usual Care or Placebo)
Heterogeneity: Chi2 = 0.38, df = 2 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 1.63 (P = 0.10)
Total (95% CI) 1757 1743 100.0 % 0.73 [ 0.47, 1.14 ]
Total events: 34 (Statin Therapy Group), 46 (Usual Care or Placebo)
Heterogeneity: Chi2 = 1.29, df = 3 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 1.39 (P = 0.16)
Test for subgroup differences: Chi2 = 0.92, df = 1 (P = 0.34), I2 =0.0%
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Analysis 5.11. Comparison 5 Sensitivity Analysis, Outcome 11 Study Size for Fatal CVD Events.
Review: Statins for the primary prevention of cardiovascular disease
Comparison: 5 Sensitivity Analysis
Outcome: 11 Study Size for Fatal CVD Events
Study or subgroup Statin Therapy Group Usual Care or Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Over 1000 participants
WOSCOPS 1997 50/3302 73/3293 94.8 % 0.68 [ 0.48, 0.98 ]
Subtotal (95% CI) 3302 3293 94.8 % 0.68 [ 0.48, 0.98 ]
Total events: 50 (Statin Therapy Group), 73 (Usual Care or Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.10 (P = 0.036)
2 Under 1000 participants
PREVEND IT 2004 4/433 4/431 5.2 % 1.00 [ 0.25, 3.95 ]
Subtotal (95% CI) 433 431 5.2 % 1.00 [ 0.25, 3.95 ]
Total events: 4 (Statin Therapy Group), 4 (Usual Care or Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.01 (P = 0.99)
Total (95% CI) 3735 3724 100.0 % 0.70 [ 0.50, 0.99 ]
Total events: 54 (Statin Therapy Group), 77 (Usual Care or Placebo)
Heterogeneity: Chi2 = 0.27, df = 1 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 2.03 (P = 0.042)
Test for subgroup differences: Chi2 = 0.27, df = 1 (P = 0.60), I2 =0.0%
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Analysis 5.12. Comparison 5 Sensitivity Analysis, Outcome 12 Study Size for Non-fatal CVD Events.
Review: Statins for the primary prevention of cardiovascular disease
Comparison: 5 Sensitivity Analysis
Outcome: 12 Study Size for Non-fatal CVD Events
Study or subgroup Statin Therapy Group Usual Care or Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Under 1000 participants
PREVEND IT 2004 18/433 21/431 100.0 % 0.85 [ 0.46, 1.58 ]
Total (95% CI) 433 431 100.0 % 0.85 [ 0.46, 1.58 ]
Total events: 18 (Statin Therapy Group), 21 (Usual Care or Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.51 (P = 0.61)
Test for subgroup differences: Not applicable
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Analysis 5.13. Comparison 5 Sensitivity Analysis, Outcome 13 Study Size for Fatal Stroke Events.
Review: Statins for the primary prevention of cardiovascular disease
Comparison: 5 Sensitivity Analysis
Outcome: 13 Study Size for Fatal Stroke Events
Study or subgroup Statin Therapy Group Usual Care or Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Over 1000 participants
WOSCOPS 1997 6/3302 4/3293 100.0 % 1.50 [ 0.42, 5.30 ]
Total (95% CI) 3302 3293 100.0 % 1.50 [ 0.42, 5.30 ]
Total events: 6 (Statin Therapy Group), 4 (Usual Care or Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.62 (P = 0.53)
Test for subgroup differences: Not applicable
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Analysis 5.14. Comparison 5 Sensitivity Analysis, Outcome 14 Study Size for total number of fatal and non-
fatal CHD, CVD and stroke events.
Review: Statins for the primary prevention of cardiovascular disease
Comparison: 5 Sensitivity Analysis
Outcome: 14 Study Size for total number of fatal and non-fatal CHD, CVD and stroke events
Study or subgroup Statin Therapy Group Usual Care or Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Over 1000 participants
Adult Japanese MEGA Study 134/3958 182/4051 32.5 % 0.75 [ 0.61, 0.94 ]
AFCAPS/TexCAPS 1998 116/3304 183/3301 33.1 % 0.63 [ 0.50, 0.80 ]
CARDS 2004 134/1428 189/1410 34.4 % 0.70 [ 0.57, 0.86 ]
Total (95% CI) 8690 8762 100.0 % 0.70 [ 0.61, 0.79 ]
Total events: 384 (Statin Therapy Group), 554 (Usual Care or Placebo)
Heterogeneity: Chi2 = 1.17, df = 2 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 5.66 (P < 0.00001)
Test for subgroup differences: Not applicable
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A P P E N D I C E S
Appendix 1. Search Strategy
CENTRAL on The Cochrane Library
#1MeSH descriptor Hydroxymethylglutaryl-CoA Reductase Inhibitors explode all trees
#2 statin or statins
#3 atorvastatin
#4 cerivastatin
#5 fluvastatin
#6 lovastatin
#7 pravastatin
#8 simvastatin
#9 lipitor
#10 baycol
#11 lescol
#12 mevacor
#13 altocor
#14 pravachol
#15 lipostat
#16 zocor
#17 rosuvastatin
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#18 (hydroxymethylglutaryl next coenzyme next reductase next inhibitor)
#19 (#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9)
#20 (#10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18)
#21 (#19 or #20)
MEDLINE on Ovid
1 exp Hydroxymethylglutaryl-CoA Reductase Inhibitors/
2 (statin or statins).tw.
3 atorvastatin.tw.
4 cerivastatin.tw.
5 fluvastatin.tw.
6 lovastatin.tw.
7 pravastatin.tw.
8 simvastatin.tw.
9 lipitor.tw.
10 baycol.tw.
11 lescol.tw.
12 mevacor.tw.
13 altocor.tw.
14 pravachol.tw.
15 lipostat.tw.
16 zocor.tw.
17 mevinolin.tw.
18 compactin.tw.
19 fluindostatin.tw.
20 rosuvastatin.tw.
21 or/1-20
22 exp Cardiovascular Diseases/
23 cardiovascular.tw.
24 heart disease$.tw.
25 coronary disease$.tw.
26 angina.tw.
27 heart failure.tw.
28 cardiac failure.tw.
29 exp Hyperlipidemia/
30 hyperlipid$.tw.
31 hypercholesterol$.tw.
32 exp Cholesterol/
33 cholesterol$.tw.
34 randomized controlled trial.pt.
35 controlled clinical trial.pt.
36 Randomized controlled trials/
37 random allocation.sh.
38 double blind method.sh.
39 single-blind method.sh.
40 or/34-39
41 exp animal/ not human/
42 40 not 41
43 clinical trial.pt.
44 exp Clinical trials/
45 (clin$ adj25 trial$).ti,ab.
46 ((singl$ or doubl$ or trebl$ or tripl$) adj (blind$ or mask$)).ti,ab.
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47 placebos.sh.
48 placebo$.ti,ab.
49 random$.ti,ab.
50 research design.sh.
51 or/43-50
52 51 not 41
53 42 or 52
54 or/22-33
55 21 and 54 and 53
EMBASE on Ovid
1 exp Hydroxymethylglutaryl Coenzyme a Reductase Inhibitor/
2 (statin or statins).tw.
3 atorvastatin.tw.
4 cerivastatin.tw.
5 fluvastatin.tw.
6 lovastatin.tw.
7 pravastatin.tw.
8 simvastatin.tw.
9 lipitor.tw.
10 baycol.tw.
11 lescol.tw.
12 mevacor.tw.
13 altocor.tw.
14 pravachol.tw.
15 lipostat.tw.
16 zocor.tw.
17 mevinolin.tw.
18 compactin.tw.
19 fluindostatin.tw.
20 rosuvastatin.tw.
21 or/1-20
22 exp Cardiovascular Disease/
23 cardiovascular.tw.
24 heart disease$.tw.
25 coronary disease$.tw.
26 angina.tw.
27 heart failure.tw.
28 cardiac failure.tw.
29 exp Hyperlipidemia/
30 hyperlipid$.tw.
31 hypercholesterol$.tw.
32 exp Cholesterol/
33 cholesterol$.tw.
34 exp lipid blood level/
35 or/22-34
36 21 and 35
37 random$.ti,ab.
38 factorial$.ti,ab.
39 (crossover$ or cross over$ or cross-over$).ti,ab.
40 placebo$.ti,ab.
41 (double$ adj blind$).ti,ab.
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42 (singl$ adj blind$).ti,ab.
43 assign$.ti,ab.
44 allocat$.ti,ab.
45 volunteer$.ti,ab.
46 Crossover Procedure/
47 Double Blind Procedure/
48 Randomized Controlled Trial/
49 Single Blind Procedure/
50 or/37-49
51 exp animal/
52 nonhuman/
53 exp animal experiment/
54 or/51-53
55 exp human/
56 54 not 55
57 50 not 56
58 36 and 57
F E E D B A C K
Failure to cite CTT paper and dangerously misleading press release, 22 February 2011
Summary
Clinical Trials Services Unit and Epidemiogical Studies Unit
The Discussion of your paper erroneously stated that the CTT collaborators had not published information about the proportional
and absolute benefits of statin therapy among people with no prior history of vascular disease, although these were published in The
Lancet in November 2010 (Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy and safety of more intensive LDL-lowering
therapy: meta-analysis of individual data from 170,000 participants in 26 randomised trials of statin therapy. Lancet 2010; 376: 1670-
81). It also stated that the CTT collaborators had been “unable to provide the relevant analysis for inclusion in our review”, but we are
not aware of having been asked by you (or anyone in your team) to provide such analyses, and wonder whether correspondence may
have gone astray.
We are concerned that these mis-statements in the Cochrane Collaboration paper (and some over-statements in the related press release,
such as the claim that “Given that low cholesterol has been shown to increase [our emphasis] the risk of death from other causes,
statins may do more harm than good in some patients”) are dangerously misleading for the public -as well as not meeting the Cochrane
Collaboration’s key principle of ‘keeping up to date’. Might it be possible for this Cochrane report to be corrected as a matter of
urgency?
Professor Colin Baigent, Professor of Epidemiology, MRC Scientist, Hon. Consultant in Public Health
Professor Rory Collins, BHF Professor of Medicine and Epidemiology
Reply
The recent CTT Lancet November 2010 paper was not available to our team at the time the review was completed and submitted
for publication to the Cochrane Database of Systematic Reviews. We agree that a data point in Figure 3 gives the proportional and
absolute effects on major vascular events of a 1mmol/l reduction in LDL cholesterol in trial participants without prior cardiovascular
disease. Our estimate of this effect and its precision is similar to the CTT estimate. I am surprised that CTT did not provide more
information on other outcomes among participants taking statins for primary prevention. In particular, others have raised the issue
of all-cause mortality in primary prevention trials (Ray et al, Arch Intern Med. 2010;170:1024-1031) and have expressed concerns
about an increased risk of diabetes in those taking statins (Sattar et al, Lancet 2010;375:735-42). We will, of course, include reference
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to the CTT paper and will remove the text stating that CTT was “unable to provide the relevant analysis for inclusion in our review”.
It should be feasible to make these changes in the next issue. Work is underway to conduct a comprehensive update of this review as
soon as possible.
Following discussions with David Tovey and Rory Collins, the press release was withdrawn and a correction issued on 8 March 2011
from by David Tovey, Editor in Chief ’s office on the homepage of the Cochrane Library (http://www.thecochranelibrary.com/details/
editorial/1029211/Correction-by-David-Tovey.html). An email was sent to all recipients of that press release, and correction was
attempted of any existing versions of the press release that were still in circulation.
Shah Ebrahim, lead author of Statins for the Primary Prevention of Cardiovascular Disease and Coordinating Editor of the Cochrane
Heart Group
Further correspondence with CTT collaboration, 7 April 2011
Summary
22 February 2011
Taylor F et al. Statins for the primary prevention of cardiovascular disease.
Cochrane Database of Systematic Reviews 2011, Issue 1
The Discussion of your paper erroneously stated that the CTT collaborators had not published information about the proportional
and absolute benefits of statin therapy among people with no prior history of vascular disease, although these were published in The
Lancet in November 2010 (Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy and safety of more intensive LDL-lowering
therapy: meta-analysis of individual data from 170,000 participants in 26 randomised trials of statin therapy. Lancet 2010; 376: 1670-
81). It also stated that the CTT collaborators had been “unable to provide the relevant analysis for inclusion in our review”, but we are
not aware of having been asked by you (or anyone in your team) to provide such analyses, and wonder whether correspondence may
have gone astray.
We are concerned that these mis-statements in the Cochrane Collaboration paper (and some over-statements in the related press release,
such as the claim that “Given that low cholesterol has been shown to increase [our emphasis] the risk of death from other causes,
statins may do more harm than good in some patients”) are dangerously misleading for the public -as well as not meeting the Cochrane
Collaboration’s key principle of ‘keeping up to date’. Might it be possible for this Cochrane report to be corrected as a matter of urgency?
Colin Baigent & Rory Collins
Reply 2 March 2011
Re: Statins for the primary prevention of cardiovascular disease, Cochrane Database of Systematic Reviews 2011, Issue 1.
Thanks for your letter of 22 February 2011. The recent CTT Lancet November 2010 paper was not available to our team at the time
the review was completed and submitted for publication to the Cochrane Database of Systematic Reviews. We agree that a data point
in Figure 3 gives the proportional and absolute effects on major vascular events of a 1mmol/l reduction in LDL cholesterol in trial
participants without prior cardiovascular disease. Our estimate of this effect and its precision is similar to the CTT estimate. I am
surprised that CTT did not provide more information on other outcomes among participants taking statins for primary prevention. In
particular, others have raised the issue of all-cause mortality in primary prevention trials (Ray et al, Arch Intern Med. 2010;170:1024-
1031) and have expressed concerns about an increased risk of diabetes in those taking statins (Sattar et al, Lancet 2010;375:735-42).
We will, of course, include reference to the CTT paper and will remove the text stating that CTT was “unable to provide the relevant
analysis for inclusion in our review”. It should be feasible to make these changes in the next issue.
The press release was referring to the association of low blood cholesterol (not cholesterol lowering by statins) with haemorrhagic
stroke which has been shown by several observational cohorts, including a large Korean civil servants cohort (n=3900 haemorrhagic
strokes), but these associations may be confounded. It would obviously be of great value to have a more reliable estimate of this effect by
randomization to statins than that reported in the recent CTT paper (RR 1.12 (95% CI: 0.93, 1.35) per 1 mmol/L reduction in LDL
cholesterol, webfigure 8) which might be achieved if more trials provided this outcome. More robust estimates would be particularly
helpful for low and middle income countries where underlying rates of haemorrhagic stroke remain high and statins, as part of a
“polypill” strategy, are being promoted for primary prevention.
We are already working on a full update of the review and have 7,000 citations to work through inclusion/exclusion criteria. In addition
to the changes for the next issue, if you want I can arrange to have your letter and my response entered in the correspondence section
linked to the review. This would enable your concerns to be immediately linked to the review and be readily available to readers of the
review. Let me know your preference.
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Shah Ebrahim
4 March 2011
Dear Shah
Thank you for your response. One quick point of clarification, the press release actually says “low cholesterol has been shown to
increase [my emphasis] the risk of death from other causes” which is clearly quite different from what you have written in the second
paragraph of your letter and is dangerously irresponsible. I wondered, therefore, if - before considering publication - you would like to
make this error clear in your letter and ensure that the statement in the press release is formally retracted.
Rory Collins
04 March 2011
Dear Rory
I agree the wording is quite wrong. The press statement has not been published, nor is it available to readers of the review itself. I will
add a sentence saying that a press release about the review contained a seriously misleading statement that “low cholesterol has been
shown to increase the risk of death from other causes”.
Shah Ebrahim
4 March 2011
Thank you for your proposal to modify your letter which is fine as far as it goes. The statement in this press release (which engendered
wide publicity) is, however, so dangerously wrong that I think the Cochrane Collaboration is obliged to issue a public retraction.
Please could you forward my correspondence to whoever is responsible for dealing with such serious misrepresentations within the
Collaboration?
Rory Collins
4 March 2011
In the first instance, if we have published something that is misleading or incorrect in the press release I would suggest that we issue a
correction in the release accompanying the next issue. I would like to explore with the writer of the release how this happened, as this
is the first time that we have had such a complaint in relation to a press release, to the best of my knowledge. Having said that I am
responsible for the sign off of press releases so that any error is entirely my responsibility.
I am making some enquiries as a matter of urgency and will let you all know when we have a proposed course of action.
David Tovey
4 March 2011
Shah Ebrahim has confirmed that the statement is wrong (see below) and, in public health terms, it is potentially a far more serious
misrepresentation than that of the risks of MMR by Wakefield and The Lancet. As a consequence, I think it requires an urgent and
specific response by the Cochrane Collaboration and should not just be “buried” in a routine press release.
Rory Collins
8 March 2011
This is to update you in relation to our current plans in relation to correction of the press release.
Firstly, we are will contact via email in the next 48 hours, all individuals and agencies that received the original press release for Issue
1 and explain the need for a correction of the offending sentence. Secondly, we will publish a correction on The Cochrane Library
homepage explaining the error. I anticipate that this will happen later today. Thirdly we will do our utmost to ensure that anywhere
where the press release is still “live”, it is modified to a more satisfactory form of words.
The Cochrane Collaboration sets a high value on quality, scientific rigour and transparency. In this instance we are grateful to you for
pointing out an error in the press release that had evaded our editorial system. Please be assured that we regarded this as a serious matter,
and have sought to implement visible and appropriate measures to correct the error. We have also learned lessons from the episode that
once implemented will reduce the chance of a similar event in the future.
David Tovey
10 March 2011
Thank you for taking some steps towards dealing with this problem as the errors of fact in both the press release, as well as those in
the related paper (see our original letter to Shah Ebrahim and his reply: attached), have had a damaging effect on public health (as
well as on the credibility of the Cochrane Collaboration). It is very much to your credit that you wish to take final responsibility (as
editor) for these errors, but should not the authors also take some of the responsibility (rather than just passing the buck) since they
presumably approved the press release which quotes them?
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I have now had an opportunity to read your Correction on the Cochrane Library website and, though welcome, it seems to me that it
is incomplete (given the errors in the original paper) and, indeed, is misleadingly half-hearted. For example, Shah Ebrahim accepts in
his letter to us that, by contrast with what he had claimed in his paper, results for the highly statistical benefits in patients with no prior
cardiovascular disease (risk ratio for major vascular events: 0.75; 95% CI 0.69 - 0.82) had been published nearly 3 months beforehand.
Your Correction would have been an opportunity to put that straight, rather than to assert that such errors do “not impact in any way
on the validity of the accompanying Cochrane Review”. Similarly, please could you explain why the claim in the press release that “low
cholesterol has been shown to increase the risk of death from other causes, statins may do more harm than good” is, according to the
assertion in your correction, “irrelevant to the underlying question being evaluated”? This does not seem to be correct.
I’m sorry not to have replied to your letter sooner, but I was waiting to see the Correction before doing so and was looking for it
on the Cochrane Collaboration website, where it does not appear. As well as having it on the Cochrane Library website, would it
not be appropriate to put this Correction (or, preferably, a more accurate one) on the Cochrane Collaboration website (and any other
Cochrane websites), especially since the statin paper is one of its featured reviews?
I do hope that you will reconsider the partial (in more than one sense) attempt that you’ve made so far to redress the serious harm that
has been caused to public health by the Cochrane Collaboration and its misinterpretation of the available evidence (which does not
seem to be at all consistent with your key principles).
Rory Collins
10 March 2011
I suspect we have reached an impasse. I really don’t accept that the response was half-hearted. To repeat, we have placed a highly visible
correction on the homepage of the product that was the subject of the press release, we have sent an email to all recipients of that press
release, and we have sought to correct any existing versions of the press release that are still in circulation.
I, not the Co-ordinating Editor, sign off the press release, so this was my error alone. It was, as you pointed out, a seriously incorrect
message - implying that the very act of reducing your serum cholesterol might cause early death - and could, if acted upon have caused
public harm. For that reason I recognised the need to act decisively and swiftly to correct any wrong impression. I made the point in
the correction that the press release mistake was based on a misunderstanding of the Cochrane Review, which had explicitly explained
that any possible association was highly unlikely to be based on cause and effect. Therefore I believe it was correct to be clear that the
press release was distinct from the review.
I recognise that you have also raised questions in relation to the content of the review. As Shah describes in his response, he has taken on
board your comments, explained why the Lancet paper was not considered in the original published version, and has sought to amend
the review appropriately at the earliest opportunity. For technical /publication reasons there will be an inevitable but short delay before
the changes are published.
I am aware that you are unlikely to agree, but I am confident that our response to the questions you have raised in relation to the press
release and the review has been appropriate, open and positive.
David Tovey
11 March 2011
I’m extremely grateful both for your careful response to my email and for what you’ve been able to do to rectify this problem. I did
have a couple of questions in my previous email which I’d be grateful if you’d consider. First, might it be possible to put the Correction
on the Cochrane Collaboration website as well, since that would be an obvious place where people alerted by the original press release
would go? Second, why do you say in the Correction that the claim in the press release that “low cholesterol has been shown to increase
the risk of death from other causes, statins may do more harm than good” is “irrelevant to the underlying question being evaluated” by
this meta-analysis of whether statins do more harm than good? I had thought that this Correction would have provided an opportunity
to indicate that errors in the original paper would also be corrected at the earliest possible opportunity.
Again, thanks for taking the issue so seriously and for going as far as you have towards repairing the damage caused.
Rory Collins
Reply
See above
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